<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0609234143
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAMICTAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMOTRIGINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        91.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DELPHARM POZNAN SPOLKA AKCYJNA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DELPHARM POZNAN SPOLKA AKCYJNA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lamictal belongs to a group of medicines called anti-epileptics.</p><p>&nbsp;</p><p>Lamictal is used to treat two conditions - <strong>epilepsy </strong>and <strong>bipolar disorder (manic depression)</strong>.</p><p>&nbsp;</p><p>Epilepsy<!--[if supportFields]><span style='font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_23428595-45bf-4ed3-9153-f234b8242310 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Lamictal treats epilepsy by blocking the signals in the brain that trigger epileptic seizures (fits).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lamictal is used to treat or prevent various types of epilepsy including the seizures associated with Lennox-Gastaut syndrome in adults and children aged 2 years and over</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lamictal may be used on its own to treat adults and children over 13 years. In children aged 2 to 12 years Lamictal may be used on its own to treat a type of epilepsy called typical absence seizures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lamictal can also be used in combination with other anti-epileptic medicines in both adults and children aged 2 years and over. Sometimes other anti- epileptic medicines may be stopped after Lamictal has been started.</p><p>&nbsp;</p><p>Bipolar disorder<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_99eb0b3d-aa65-47f8-9bb9-67de584d4878 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Lamictal treats bipolar disorder (sometimes called <em>manic depression</em>), a condition which causes extreme mood swings, with periods of mania (excitement or euphoria) alternating with periods of depression (deep sadness or despair), this medicine Should not be used as acute treatment for this condition. For adults aged 18 years and over, Lamictal can be used to prevent the mood swings that occur in bipolar disorder. It is not yet known how Lamictal works in the brain to have this effect.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>on&rsquo;t take Lamictal:<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b166bdad-36a8-422b-9d4e-38cb439f894e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>if you are allergic (<em>hypersensitive</em>) to lamotrigine or any of the other ingredients of Lamictal tablets (listed in section 6).</strong></p><p>&Uacute; if you think this applies to you, <strong>don&rsquo;t take Lamictal </strong>until you have checked with your doctor.</p><p>Take special care with Lamictal<!--[if supportFields]><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_608d0742-b53e-4a69-acb7-6890827d8c71 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Before you take Lamictal your doctor needs to know:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any liver or kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever developed a rash after taking lamotrigine or other medicines for bipolar disorder or epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever developed meningitis after taking lamotrigine (read the description of these symptoms in the &lsquo;Possible Side Effects&rsquo; section (Section 4) of this leaflet: Rare side effects)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are already taking medicine that contains lamotrigine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a condition called Brugada syndrome (a genetic disease that affects the heart), or other heart problems.</p><p>&nbsp;</p><p>If any of these apply to you:</p><p>Tell your doctor, who may decide to lower the dose, or that Lamictal is not suitable for you.<!--[if supportFields]><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ea3cb8e4-cf66-4a66-b446-c3bd1b058d63 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Conditions you need to look out for:</strong></p><p>Important information about potentially serious skin reaction<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fea4f8a4-7e16-44f8-ba02-16e1ca3428cc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>A small number of people taking Lamictal get an allergic reaction or potentially serious skin reaction, which may develop into more serious problems such as organ failure if they are not treated. You need to know the symptoms to look out for while you are taking Lamictal.</p><p>&nbsp;</p><p>&Uacute; Read the descriptions on these symptoms in Section 4 of this leaflet under &lsquo;Potentially serious skin reaction&rsquo;<em>.</em><!--[if supportFields]><i style='mso-bidi-font-style:normal'><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;font-weight:
normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_253d92f0-5b3e-4965-857e-092ae6a464e7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;font-weight:normal'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>&nbsp;</p><p>Serious immune system condition (haemophagocytic lymphohistiocytosis or HLH)<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1bcb758d-0a4f-42a9-bdfe-db02d3351ab5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>A serious immune system condition, in which the part of the body that fights disease is overactive. Although it has been reported very rarely in people taking Lamictal, it can be life-threatening. If you have any of the associated symptoms, immediately report them to your doctor.</p><p>&Uacute; &nbsp;Read the descriptions of these symptoms in Section 4 of this leaflet under &lsquo;Serious immune system condition&rsquo;.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d4c0b7d8-b86d-4f6b-b279-f39df3c11d96 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><em>&nbsp;</em></p><p>Thoughts of harming yourself or suicide<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_102c5f94-402c-4b9d-888a-bd60e694c675 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Anti-epileptic medicines are used to treat several conditions, including epilepsy and bipolar disorder. There have been a small number of reports of suicidal behaviour (including suicidal thoughts and suicide attempts) in patients being treated with anti-epileptic medicines such as Lamictal. If at any time you have these thoughts, <strong>contact your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p>If you are taking Lamictal to prevent extreme mood swings, you may not experience the full effect for several weeks. Occasionally, the symptoms of depression or bipolar disorder may include thoughts of harming yourself or committing suicide. This risk may be higher:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when starting treatment or changing dose for patients who currently have (or have previously had) thoughts of harming themselves or committing suicide for young adults.</p><p>&nbsp;</p><p>If you have distressing thoughts or experiences, or if you notice that you feel worse or develop new symptoms while you&rsquo;re taking Lamictal:</p><p>Contact a doctor immediately or go to the nearest hospital for help.<!--[if supportFields]><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_38861992-02c7-4eec-8827-a3346040732a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>You may find it helpful to tell a family member, caregiver or close friend </strong>that you can become depressed or have significant changes in mood, and ask them to read this leaflet. You might ask them to tell you if they are worried about your depression or other changes in your behaviour.</p><p>&nbsp;</p><p>LAMICTAL should not be given to people aged under 18 years to treat bipolar disorder. Medicines to treat depression and other mental health problems increase the risk of suicidal thoughts and behaviour in children and adolescents aged less than 18 years.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you&rsquo;re taking Lamictal for epilepsy<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_19f395b6-9afb-4a12-9376-6d4a9feb0cce \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>The seizures in some types of epilepsy may occasionally become worse or happen more often while you&rsquo;re taking Lamictal. Some patients may experience severe seizures, which may cause serious health problems. If your seizures happen more often or if you experience a severe seizure while you&rsquo;re taking Lamictal:</p><p>&Uacute;&nbsp; Contact a doctor as soon as possible<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3321b3cf-4f51-4650-b39d-af8ffad7fb3c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Other medicines and Lamictal</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor or pharmacist if you are taking any other medicines</strong>, have taken any recently, or start taking new ones. This includes medicines bought without a prescription.</p><p>Some medicines may affect how Lamictal works, or make it more likely that people will have side effects. Lamictal can also affect how some other medicines work. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>phenytoin, primidone </strong>or <strong>phenobarbitone</strong>, used to treat <strong>epilepsy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>risperidone</strong>, used to treat <strong>mental health problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>valproate </strong>and <strong>carbamazepine</strong>, used to treat both <strong>epilepsy </strong>and <strong>mental health problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin</strong>, which is an <strong>antibiotic</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>Human Immunodeficiency Virus (HIV) infection </strong>(a combination of lopinavir and ritonavir or atazanavir and ritonavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Oestrogen-containing products, including</strong><strong> </strong><strong>hormonal contraceptives</strong><strong> (</strong><em>see below)</em><strong> </strong><strong>&nbsp;</strong><strong>and hormone replacement therapy </strong>(HRT) <em>.</em></p><p>&Uacute; <strong>Tell your doctor or pharmacist</strong> if you are taking any of these, or if you start or stop taking any. Your doctor may decide to adjust your dose.</p><p>&nbsp;</p><p>Hormonal contraceptive pills can affect the way Lamictal works<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5a070917-f4bf-43d5-bf89-b4c5f78d73f2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Your doctor may recommend that you take a particular type of hormonal contraceptive pill, or use another method of contraception, such as condoms, a cap or coil. If you are taking a hormonal contraceptive pill, or if you plan to start or stop taking one:</p><p>&Uacute; <strong>Talk to your doctor, </strong>who will discuss suitable methods of contraception with you.</p><p>&nbsp;</p><p>Lamictal may also affect the way hormonal contraceptives work<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5bd2f626-4a08-45f3-8694-8fe3b13c5b88 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>If you are taking a hormonal contraceptive pill, Lamictal may affect how well this works. If you notice any changes in your menstrual pattern, such as breakthrough bleeding or spotting between periods:</p><p>&Uacute; <strong>Tell your doctor</strong>. These may be signs that Lamictal is affecting how well your contraceptive pill is working.</p><p>&nbsp;</p><p>Laboratory tests<!--[if supportFields]><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0e176da4-0448-4702-85f7-2467187eb53c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Lamictal may interfere with some laboratory tests to detect other drugs. If you require a laboratory test, tell your doctor or hospital that you are taking Lamictal.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding<!--[if supportFields]><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_eee52662-68bb-46df-8190-596668ea4a12 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&Uacute; <strong>Talk to your doctor if you&rsquo;re pregnant, if you might be pregnant, or if you&rsquo;re planning to become pregnant. </strong>There may be an increased risk of babies developing a cleft lip or cleft palate if Lamictal is taken during the first few months of pregnancy.</p><p>&Uacute; <strong>Talk to your doctor if you&rsquo;re breast feeding or planning to breast feed. </strong>The active ingredient in Lamictal passes into breast milk and may affect your baby. Your doctor will discuss the risks and benefits of breast feeding while you&rsquo;re taking Lamictal.</p><p>&Uacute; Are you pregnant or plan to become pregnant. It is not known if LAMICTAL may harm your unborn baby...</p><p>&Uacute; Are breastfeeding. LAMICTAL passes into breast milk and may cause side effects in a breastfed baby. If you breastfeed while taking LAMICTAL, watch your baby closely for trouble breathing, episodes of temporarily stopping breathing, sleepiness, or poor sucking. Call your baby&rsquo;s healthcare provider right away if you see any of these problems. Talk to your healthcare provider about the best way to feed your baby if you take LAMICTAL.</p><p>Driving and using machines<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8e9e48b5-58ce-4d2b-b9bf-082696ad14ed \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Lamictal can cause drowsiness, dizziness and double vision.</p><p>&Uacute; <strong>Don&rsquo;t drive or operate machines </strong>unless you are sure you&rsquo;re not affected.</p><p>&nbsp;</p><p>If you have epilepsy, talk to your doctor about driving and using machines.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_acc94ab4-92a0-4ebe-85f0-9f34d5614be5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
lang=EN-GB style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
font-weight:normal;mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take Lamictal exactly as your doctor has told you to. </strong>Check with your doctor or pharmacist if you&#39;re not sure.</p><p>&nbsp;</p><p>How much to take<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3cdd4aea-3414-4eb2-9fe1-7243558b9073 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>It may take a while to find the best dose of Lamictal for you. The dose you take will depend on:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your age and weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether you are taking Lamictal with other medications</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether you have any kidney or liver problems</p><p>&nbsp;</p><p>Your doctor will prescribe a low dose to start, and gradually increase the dose over a few weeks until you reach a dose that works for you (the <em>effective dose</em>). <strong>Never take more Lamictal than your doctor tells you to.</strong></p><p><strong>&nbsp;</strong></p><p>Epilepsy<!--[if supportFields]><span style='font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_118f67f9-5e19-4d4a-9eb7-8cf54a27b624 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Adults and adolescents over 13 years of age:</strong></p><p><strong>&nbsp;</strong></p><p>The usual effective dose of Lamictal is between 100 mg and 700 mg each day.</p><p>&nbsp;</p><p>Children (2 to 12 years of age):<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_48862ee5-ebb2-425f-8e1b-419706018b5b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>The usual effective dose of Lamictal depends on body weight &ndash; usually it&rsquo;s between 1 mg and 10 mg for each kilogram of the child&rsquo;s weight, up to a maximum of 400 mg daily.</p><p>&nbsp;</p><p>Lamictal is not recommended for children aged under 2 years.</p><p>&nbsp;</p><p>Bipolar disorder<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_cc91cb65-0945-4237-9646-83d03c3d53cb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Adults 18 years of age and over:</strong></p><p><strong>&nbsp;</strong></p><p>The usual effective dose of Lamictal is between 100 mg and 400 mg each day.</p><p>&nbsp;</p><p>Children and adolescents less than 18 years of age:<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d811115b-8856-45d6-9e48-212a6371deed \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Lamictal is not recommended for children and adolescents aged less than 18 years.</p><p>&nbsp;</p><p>How to take<!--[if supportFields]><span style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8fd05e73-6078-4c64-980e-0b1b2ad28732 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Take your dose of Lamictal once or twice a day, as your doctor advises. It can be taken with or without food.</p><p>&nbsp;</p><p>Your doctor may also advise you to start or stop taking other medicines, depending on what condition you&rsquo;re being treated for and the way you respond to treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swallow your tablets whole</strong>. Don&rsquo;t break, chew or crush them</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Always take the full dose </strong>that your doctor has prescribed. Never take only part of a tablet.</p><p>&nbsp;</p><p>If you forget to take a single dose of Lamictal<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_51084b31-43cc-4765-9c8a-27674a1f7be1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Take it as soon as you remember unless your next dose is due in less than 4 hours, in which case skip the missed dose and take your next dose at the normal time.</p><p>&nbsp;</p><p>&Uacute; Don&#39;t take a double dose to make up for a missed dose.<!--[if supportFields]><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e9ffccc6-2317-460c-b04e-5d8410fbcafa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take multiple doses of Lamictal</strong></p><p>&Uacute; <strong>Ask your doctor for advice on how to start taking it again, </strong>even if you only stop for a few days.</p><p>&nbsp;</p><p>If you take too much Lamictal<!--[if supportFields]><span style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3d731029-0897-4bec-895f-2e27fbb23d03 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>If you take too much Lamictal you may be <strong>more likely to have serious side effects which may be fatal. </strong>Possible side effects if you take too much Lamictal include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid, uncontrollable eye movements (<em>nystagmus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clumsiness and lack of co-ordination, affecting your balance (<em>ataxia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired or loss of consciousness, fits (<em>convulsions</em>) or coma.</p><p>&Uacute; <strong>If you take too much Lamictal contact your doctor or your nearest hospital emergency department immediately</strong>. If possible, show them the Lamictal pack.</p><p>&nbsp;</p><p>Don&rsquo;t stop Lamictal without advice<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6ef572a2-520e-49de-a7d2-ec8d4d16ee84 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Take Lamictal for as long as your doctor recommends. Don&rsquo;t stop unless your doctor advises you to.</p><p>&nbsp;</p><p>If you&rsquo;re taking Lamictal for epilepsy<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_867a399b-5a6a-4383-a629-8f999dcf46fd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>To stop taking Lamictal, it is important that the dose is reduced gradually, over about 2 weeks. If you suddenly stop taking Lamictal, your epilepsy may come back or get worse.</p><p>&Uacute; <strong>Speak to your doctor before stopping Lamictal.</strong></p><p>&nbsp;</p><p>If you&rsquo;re taking Lamictal for bipolar disorder<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6928b1be-0274-4ea4-936e-23cb54866030 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>If you are taking Lamictal to prevent extreme mood swings, you may not experience the full effect for several weeks. If you stop taking Lamictal, your dose will not need to be reduced gradually. But you should still talk to your doctor first, if you want to stop taking Lamictal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Lamictal can cause side effects, but not everybody gets them.</p><p>&nbsp;</p><p>&nbsp;</p><p>Conditions you need to look out for:<!--[if supportFields]><span style='font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_43903221-5974-42d1-afad-0912eb347679 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Potentially serious skin reaction</strong></p><p><strong>&nbsp;</strong></p><p>A small number of people taking Lamictal get an allergic reaction or potentially serious skin reaction, which may develop into more serious problems if they are not treated. Severe allergic reactions are rare (these may affect <strong>up to 1 in 1,000 people</strong>).</p><p>These symptoms are more likely to happen during the first few months of treatment with Lamictal, especially if the dose is too high or if the dose is increased too quickly, or if Lamictal is taken with a medicine called <em>valproate</em>. Serious skin reactions are more common in children. Symptoms of these allergic reactions include:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>skin rashes or redness, </strong>which may develop into severe skin reactions including widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Erythema multiforme</em><em>,</em><em> </em><em>Stevens-Johnson syndrome </em>and <em>toxic epidermal necrolysis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sore mouth or eyes<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5ccbdb30-c7c9-4e23-8ebe-32eeb232e6fc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>a high temperature </strong>(fever), flu-like symptoms or drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>swelling around your face, </strong>or <strong>swollen glands </strong>in your neck, armpit or groin</p><p>&nbsp;</p><p><strong>In many cases</strong>, these symptoms will be signs of less serious side effects. <strong>But you must be aware that they are potentially serious and can develop into more serious problems, </strong>such as organ failure (kidney and liver failure) and a serious blood clotting disorder which can cause unexpected bruising or bleeding (<em>disseminated intravascular coagulation</em>). These conditions are very rare (<strong>up to 1 in 10,000 </strong>people).</p><p>&Uacute; <strong>Contact a doctor immediately </strong>if you have any of these symptoms<strong>.</strong></p><p>&nbsp;</p><p>Serious immune system condition (haemophagocytic lymphohistiocytosis or HLH)<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-US;mso-bidi-language:AR-SA;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_cad5ff89-b507-4f4b-ae9d-93e2eece1138 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-US;mso-bidi-language:AR-SA;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>A serious immune system condition, in which the part of the body system that fights disease is overactive, has been reported while taking Lamictal. Although, it has been reported very rarely (up to 1 in 10 000, people), it can be life-threatening, so it is important that you know the symptoms to look out for. Symptoms include:<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-US;mso-bidi-language:AR-SA;font-weight:normal;
mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b82f2716-b5ce-460a-b36e-88760145fc4a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-US;mso-bidi-language:AR-SA;font-weight:normal;
mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a high temperature (fever),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble walking or seeing, and fits (seizures) for the first time or happening more often</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged liver and/or spleen with pain and/or tenderness in the region towards the top of the stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and/or eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen glands in the neck, armpit and/or groin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding and/or bruising more easily; looking pale, feeling tired.</p><p>&nbsp;</p><p>In most cases these symptoms may be signs of less serious side effects, but you must be aware that they can be signs of a condition which can be serious if not recognised early.</p><p>&Uacute; <strong>Contact a doctor immediately</strong> if you have any of these symptoms.</p><p>&nbsp;</p><p>Liver and blood problems<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e6ddf1ce-8b82-4624-96f6-91ceb66afe27 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These have been reported rarely while taking Lamictal <strong>(in up to 1 in 1,000 </strong>people). The following symptoms may be accompanied by a general feeling of being sick or unwell:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain and/or tenderness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexpected bleeding or bruising, or the fingers turning blue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sore throat, or more infections (such as colds) than usual&nbsp;&nbsp;&nbsp;</p><p>&Uacute; <strong>Contact a doctor immediately if you notice any of these symptoms. </strong>Your doctor may decide to carry out tests on your liver, kidneys or blood, and may tell you to stop taking Lamictal.</p><p>&nbsp;</p><p>Seizures in Epilepsy worsening<!--[if supportFields]><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_352f4f74-8b98-4d35-b057-9d9882b5829b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>In people who <strong>already have epilepsy</strong>: <strong>seizures happening more often. </strong>This is very rare (<strong>up to 1 in 10,000</strong>) people taking Lamictal.</p><p>&Uacute; <strong>Tell your doctor as soon as possible </strong>if this happens</p><p>&nbsp;</p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clumsiness and lack of co-ordination (<em>ataxia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred or double vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea) </em>or being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash.</p><p>&nbsp;</p><p>Common side effects<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e689a85c-3164-43d2-894a-2e7c131700f6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression, agitation or irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping (<em>insomnia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling drowsy or tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid, uncontrollable eye movements (<em>nystagmus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your back, joints or elsewhere.</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare side effects<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_44a90328-4fcf-47e5-a842-b2ae3085948a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 1,000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (Erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe skin reaction (<em>Stevens-Johnson syndrome</em>) see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy eyes with discharge and crusty eyelids (<em>conjunctivitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a group of side effects together including headache, fever, nausea, vomiting, stiff neck, rash, unusual sensitivity to light, muscle pains, chills, confusion and drowsiness. This may be caused by an inflammation of the membranes that cover the brain and spinal cord (<em>meningitis</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual hair loss or thinning (alopecia)</p><p>&nbsp;</p><p>Very rare side effects<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3236ebdd-db9b-437a-9b72-a7d006e67915 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 10,000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe skin reaction including extensive peeling of the skin (<em>toxic epidermal necrolysis</em>), see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multi-organ failure or a serious blood clotting disorder which can cause unexpected bruising or bleeding (<em>disseminated intravascular coagulation</em>), see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a serious immune system condition (<em>haemophagocytic lymphohistiocytosis</em> or HLH), see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face (<em>oedema</em>) or swollen glands in the neck, armpits or groin (<em>lymphadenopathy</em>), see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red nodules or patches on the skin (pseudolymphoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a high temperature (<em>fever), </em>see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in people who already have epilepsy, seizures happening more often, see also the information at the beginning of Section 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidney (<em>tubulointerstitial nephritis</em>), which may occur in association with inflammation of the eye (<em>uveitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable bodily movements (<em>tics</em>), uncontrollable muscle spasms affecting the eyes, head and torso (<em>choreoathetosis</em>), or other unusual body movements such as jerking, shaking or stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling wobbly or unsteady when you move around</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion or agitation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing or hearing things that aren&rsquo;t really there (<em>hallucinations</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in people who already have Parkinson&rsquo;s disease, a worsening of the symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus (symptoms may include back or joint pain which sometimes may be accompanied by fever and/or general ill health)</p><p>&nbsp;</p><p>Very rare side effects that may show up in blood tests<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fa89e92e-db75-49f4-b3ff-fbecc1edc6be \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 10,000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of red blood cells (<em>anaemia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of white blood cells (<em>neutropenia, leucopenia, agranulocytosis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of blood platelets, the cells that help blood to clot (<em>thrombocytopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reduced number of all these types of cells (<em>pancytopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disorder of the bone marrow called <em>aplastic anaemia</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in antibodies (immunoglobulins).</p><p>&Uacute; <strong>Tell your doctor or pharmacist </strong>if any of the side effects become <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_98012f2a-bd66-41bd-88c6-25a31bee2ce1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Lamictal after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Lamictal below 30&deg;C. Keep dry.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking Lamictal, it is important to return any remnants which are left over to your pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Lamictal contains<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0b1a21ce-f800-4d5a-ab3d-2a0b38ad8cd6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>The active substance is lamotrigine.<!--[if supportFields]><span style='font-size:11.5pt;
line-height:150%;font-family:"Times New Roman",serif;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;color:black;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA;font-weight:normal'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_7f4ad319-9b16-43db-8f08-c65f6556cdfb
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.5pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;color:black;
mso-fareast-language:EN-US;mso-bidi-language:AR-SA;font-weight:normal'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Each tablet contains 25, 50 or 100 mg lamotrigine.</p><p>The other ingredients are:</p><p>Microcrystalline cellulose, Povidone, Sodium starch glycolate, Iron oxide yellow (E172), Magnesium stearate.</p><p>LAMICTAL tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lamictal Tablets 25 mg are pale-yellowish brown, multifaceted super elliptical flat tablet, engraved “GSEC7” on one side and “25” on the other. 
Lamictal Tablets 50 mg are pale-yellowish brown, multifaceted super elliptical flat tablet, engraved “GSEE1” on one side and “50” on the other. 
Lamictal Tablets 100 mg are pale-yellowish brown, multifaceted super elliptical flat tablet, engraved “GSEE5” on one side and “100” on the other. 

Not All pack sizes may be marketed.

Lamictal is a trademark owned by or licensed to the GSK group of companies.
© 2024 GSK group of companies. All Rights Reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p><strong>Packed by: </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact: </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GSK - Head Office, Jeddah </strong></p><p>Tel: +966-12-6536666</p><p>Mobile : +966-56-904-9882</p><p>Email : gcc.medinfo@gsk.com&nbsp;</p><p>Website : https://gskpro.com/en-sa/</p><p>P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:roundrect
 id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_8" o:spid="_x0000_s1026"
 style='width:452pt;height:259.05pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:middle' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" strokecolor="black [3200]" strokeweight="1.5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:9.0pt;line-height:13.3pt;mso-line-height-rule:
    exactly'><b style='mso-bidi-font-weight:normal'><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>To report any side
    effect(s):<o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><i style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial'>Kingdom of Saudi Arabia<o:p></o:p></span></i></b></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt;font-family:
    "Times New Roman",serif;mso-hansi-font-family:Arial;mso-bidi-font-family:
    Arial'>-National Pharmacovigilance centre (NPC)<o:p></o:p></span></b></p>
    <p class=MsoListParagraph style='margin-left:.5in;mso-pagination:widow-orphan;
    mso-list:l0 level1 lfo1;mso-layout-grid-align:none'><![if !supportLists]><span
    style='font-size:11.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US;mso-bidi-language:
    AR-SA'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;
    mso-fareast-theme-font:minor-latin;color:black;mso-fareast-language:EN-US;
    mso-bidi-language:AR-SA'>SFDA Call Center: 19999 <o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:1.95pt;margin-right:0in;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l0 level1 lfo1;
    tab-stops:44.95pt 45.0pt'><![if !supportLists]><span lang=FR
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:
    FR'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=FR
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial;mso-ansi-language:
    FR'>E-mail :<span style='color:blue;letter-spacing:-.05pt'> </span></span><a
    href="mailto:npc.drug@sfda.gov.sa"><span lang=FR style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial;mso-ansi-language:FR'>npc.drug@sfda.gov.sa</span></a><u
    style='text-underline:blue'><span lang=FR style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial;color:blue;mso-ansi-language:FR'> </span></u><span
    lang=FR style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-hansi-font-family:Arial;mso-ansi-language:FR'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:1.95pt;margin-right:0in;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l0 level1 lfo1;
    tab-stops:44.95pt 45.0pt'><![if !supportLists]><span lang=EN-US
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol;mso-ansi-language:EN-US'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:
    11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:Arial;
    mso-bidi-font-family:Arial;mso-ansi-language:EN-US'>Website: </span><a
    href="https://ade.sfda.gov.sa"><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:+mn-ea;mso-bidi-font-family:+mn-cs;mso-font-kerning:
    12.0pt'>https://ade.sfda.gov.sa</span></a><span lang=EN-US
    style='mso-ansi-language:EN-US'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:2.0pt;margin-right:0in;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:0in;
    tab-stops:44.95pt 45.0pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt;font-family:
    "Times New Roman",serif;mso-hansi-font-family:Arial;mso-bidi-font-family:
    Arial'>-GSK - Head Office, Jeddah<o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt;font-family:
    "Times New Roman",serif;mso-hansi-font-family:Arial;mso-bidi-font-family:
    Arial'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.3pt;
    mso-line-height-rule:exactly;mso-list:l2 level1 lfo2'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>Tel:<span
    style='letter-spacing:2.95pt'> </span>+966-12-6536666<o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:3.0pt;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l2 level1 lfo2'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>Mobile:
    +966-56-904-9882<o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:3.0pt;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l2 level1 lfo2'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol;mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:
    AR-SA'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>Email: </span><u><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-bidi-font-family:+mn-cs;color:blue;mso-font-kerning:12.0pt;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'>s</span></u><a
    href="mailto:audi.safety@gsk.com"><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:+mn-cs;
    mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>audi.safety@gsk.com</span></a><u><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-bidi-font-family:+mn-cs;color:blue;mso-font-kerning:12.0pt;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'><span style='mso-spacerun:yes'>  </span><o:p></o:p></span></u></p>
    <p class=MsoListParagraph style='margin-left:.5in;mso-add-space:auto;
    line-height:115%;mso-pagination:widow-orphan;mso-list:l1 level1 lfo3;
    tab-stops:list .5in;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    lang=EN-US style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:
    Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
    mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>website: </span><a
    href="https://gskpro.com/en-sa/"><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:+mn-cs;
    mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>https://gskpro.com/en-sa/</span></a><u><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-bidi-font-family:+mn-cs;color:blue;mso-font-kerning:12.0pt;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'> </span></u><span lang=EN-US
    style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:3.0pt;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;line-height:120%;
    mso-list:l2 level1 lfo2'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;line-height:120%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;
    line-height:120%;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial'>P.O. Box 55850, Jeddah 21544, Saudi
    Arabia<o:p></o:p></span></p>
    <p class=MsoNormal align=center style='text-align:center'><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:roundrect><![endif]--><img width="607" height="351" alt="Rectangle: Rounded Corners: To report any side effect(s):
Kingdom of Saudi Arabia
-National Pharmacovigilance centre (NPC)
•	SFDA Call Center: 19999 
•	E-mail : npc.drug@sfda.gov.sa 
•	Website: https://ade.sfda.gov.sa

-GSK - Head Office, Jeddah

•	Tel: +966-12-6536666
•	Mobile: +966-56-904-9882
•	Email: saudi.safety@gsk.com  
•	website: https://gskpro.com/en-sa/ 
•	P.O. Box 55850, Jeddah 21544, Saudi Arabia

" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:452pt;height:259.05pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p><strong>Manufactured by: </strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p><strong>Packed by: </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact: </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GSK - Head Office, Jeddah </strong></p><p>Tel: +966-12-6536666</p><p>Mobile : +966-56-904-9882</p><p>Email : gcc.medinfo@gsk.com&nbsp;</p><p>Website : https://gskpro.com/en-sa/</p><p>P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:roundrect
 id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_8" o:spid="_x0000_s1026"
 style='width:452pt;height:259.05pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:middle' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" strokecolor="black [3200]" strokeweight="1.5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:9.0pt;line-height:13.3pt;mso-line-height-rule:
    exactly'><b style='mso-bidi-font-weight:normal'><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>To report any side
    effect(s):<o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><i style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial'>Kingdom of Saudi Arabia<o:p></o:p></span></i></b></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt;font-family:
    "Times New Roman",serif;mso-hansi-font-family:Arial;mso-bidi-font-family:
    Arial'>-National Pharmacovigilance centre (NPC)<o:p></o:p></span></b></p>
    <p class=MsoListParagraph style='margin-left:.5in;mso-pagination:widow-orphan;
    mso-list:l0 level1 lfo1;mso-layout-grid-align:none'><![if !supportLists]><span
    style='font-size:11.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US;mso-bidi-language:
    AR-SA'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;
    mso-fareast-theme-font:minor-latin;color:black;mso-fareast-language:EN-US;
    mso-bidi-language:AR-SA'>SFDA Call Center: 19999 <o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:1.95pt;margin-right:0in;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l0 level1 lfo1;
    tab-stops:44.95pt 45.0pt'><![if !supportLists]><span lang=FR
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:
    FR'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=FR
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial;mso-ansi-language:
    FR'>E-mail :<span style='color:blue;letter-spacing:-.05pt'> </span></span><a
    href="mailto:npc.drug@sfda.gov.sa"><span lang=FR style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial;mso-ansi-language:FR'>npc.drug@sfda.gov.sa</span></a><u
    style='text-underline:blue'><span lang=FR style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial;color:blue;mso-ansi-language:FR'> </span></u><span
    lang=FR style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-hansi-font-family:Arial;mso-ansi-language:FR'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:1.95pt;margin-right:0in;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l0 level1 lfo1;
    tab-stops:44.95pt 45.0pt'><![if !supportLists]><span lang=EN-US
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol;mso-ansi-language:EN-US'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:
    11.0pt;font-family:"Times New Roman",serif;mso-hansi-font-family:Arial;
    mso-bidi-font-family:Arial;mso-ansi-language:EN-US'>Website: </span><a
    href="https://ade.sfda.gov.sa"><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:+mn-ea;mso-bidi-font-family:+mn-cs;mso-font-kerning:
    12.0pt'>https://ade.sfda.gov.sa</span></a><span lang=EN-US
    style='mso-ansi-language:EN-US'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:2.0pt;margin-right:0in;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:0in;
    tab-stops:44.95pt 45.0pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt;font-family:
    "Times New Roman",serif;mso-hansi-font-family:Arial;mso-bidi-font-family:
    Arial'>-GSK - Head Office, Jeddah<o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-left:9.0pt'><b style='mso-bidi-font-weight:
    normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt;font-family:
    "Times New Roman",serif;mso-hansi-font-family:Arial;mso-bidi-font-family:
    Arial'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.3pt;
    mso-line-height-rule:exactly;mso-list:l2 level1 lfo2'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>Tel:<span
    style='letter-spacing:2.95pt'> </span>+966-12-6536666<o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:3.0pt;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l2 level1 lfo2'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>Mobile:
    +966-56-904-9882<o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:3.0pt;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;mso-list:l2 level1 lfo2'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol;mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:
    AR-SA'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>Email: </span><u><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-bidi-font-family:+mn-cs;color:blue;mso-font-kerning:12.0pt;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'>s</span></u><a
    href="mailto:audi.safety@gsk.com"><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:+mn-cs;
    mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>audi.safety@gsk.com</span></a><u><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-bidi-font-family:+mn-cs;color:blue;mso-font-kerning:12.0pt;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'><span style='mso-spacerun:yes'>  </span><o:p></o:p></span></u></p>
    <p class=MsoListParagraph style='margin-left:.5in;mso-add-space:auto;
    line-height:115%;mso-pagination:widow-orphan;mso-list:l1 level1 lfo3;
    tab-stops:list .5in;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    lang=EN-US style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:
    Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
    mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    12.0pt;mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>website: </span><a
    href="https://gskpro.com/en-sa/"><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:+mn-cs;
    mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>https://gskpro.com/en-sa/</span></a><u><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-bidi-font-family:+mn-cs;color:blue;mso-font-kerning:12.0pt;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'> </span></u><span lang=EN-US
    style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:3.0pt;margin-right:-68.5pt;
    margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;line-height:120%;
    mso-list:l2 level1 lfo2'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;line-height:120%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;
    line-height:120%;font-family:"Times New Roman",serif;mso-hansi-font-family:
    Arial;mso-bidi-font-family:Arial'>P.O. Box 55850, Jeddah 21544, Saudi
    Arabia<o:p></o:p></span></p>
    <p class=MsoNormal align=center style='text-align:center'><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:roundrect><![endif]--><img width="607" height="351" alt="Rectangle: Rounded Corners: To report any side effect(s):
Kingdom of Saudi Arabia
-National Pharmacovigilance centre (NPC)
•	SFDA Call Center: 19999 
•	E-mail : npc.drug@sfda.gov.sa 
•	Website: https://ade.sfda.gov.sa

-GSK - Head Office, Jeddah

•	Tel: +966-12-6536666
•	Mobile: +966-56-904-9882
•	Email: saudi.safety@gsk.com  
•	website: https://gskpro.com/en-sa/ 
•	P.O. Box 55850, Jeddah 21544, Saudi Arabia

" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:452pt;height:259.05pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS Version Number: GDS53
Date of issue: 08 July 2024

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">لاميكتال ينتمي إلى مجموعة أدوية تسمى مضادات الصرع.</p><p dir="RTL">لاميكتال يستخدم لعلاج حالتين مرضيتين <strong>الصرع </strong>و<strong>الاضطراب ثنائي القطب (كآبي هوسي)</strong>.</p><p dir="RTL"><strong>الصرع</strong></p><p dir="RTL">لاميكتال يعالج الصرع بواسطة حجب اشارات في المخ التي تستحدث نوﺑﺎت الصرع (نوﺑﺎت).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاميكتال يستخدم لعلاج و منع أنواع مختلفة من الصرع تشمل النوﺑﺎت المرتبطة بمتلازمة لينوكس &ndash;جاستوت في البالغين والأطفال من عمر سنتين فما فوق .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاميكتال يجوز استخدامه بمفرده لعلاج البالغين والأطفال من عمر ١٣ سنة فما فوق. يجوز استخدام لاميكتال بمفرده في الأطفال من سن ٢ إلى ١٢ عام اً لعلاج نوع من الصرع يسمى نوﺑﺎت الغياب النمطية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاميكتال يجوز استخدامه مع أدوية أخرى لعلاج تلك الحالات في البالغين و الأطفال من عمر سنتين. أحياناً يتم إيقاف استخدام أدوية مضادات الصرع الأخرى بعد البدء ﺑﺎستخدام لاميكتال .</p><p dir="RTL"><strong>الاضطراب ثنائي القطب</strong></p><p dir="RTL">لاميكتال يعالج الاضطراب ثنائي القطب (أحياناً يسمى كآبي هوسي)، هي حالة تسبب تقلبات مزاج حادة، مع نوﺑﺎت جنون (هياج أو نشوة) متعاقب مع نوﺑﺎت من الاكتئاب (اكتئاب عميق أو اليأس)، لا يجب تناول هذا الدواء كعلاج النوﺑﺎت الحادة لهذا المرض. للبالغين من عمر ١٨ سنة فأكثر، يمكن استخدام لاميكتال لعلاج تقلبات المزاج التي تحدث في الاضطراب ثنائي القطب. ليس من المعروف حتى الآن كيف يزاول لاميكتال عمله في المخ ليعطي هذا المفعول.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول لاميكتال</strong><strong>:</strong></p><p dir="RTL"><strong>إذا كنت مصاﺑﺎً بحساسية (مفرط الحساسية) لللاموتريجين، أو لأي من المكونات الأخرى في لاميكتال (مدرجة ﺑﺎلفقرة ٦).</strong></p><p dir="RTL">&larr;&nbsp; إذا كنت تظن أن ما سبق ينطبق عليك، <strong>لاتتناول لاميكتال </strong>حتى تتأكد من طبيبك .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يجب توخي الحذر الشديد عند استعمال لاميكتال</strong></p><p dir="RTL"><strong>قبل تناول لاميكتال يحتاج طبيبك معرفة</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلية أو الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة سابقاً بطفح جلدي بعد تناول لاموتريجين أو أي أدوية أخرى لعلاج الاضطراب ثنائي القطب والصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة سابقاً ﺑﺎلتهاب السحايا بعد تناول لاموتريجين (اقرأ وصف هذه الأعراض في قسم &quot;أعراض جانبية محتملة&quot; (قسم 4) في هذه النشرة: أعراض جانبية نادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ﺑﺎلفعل دواءً يحتوي على لاموتريجين .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة تُدعى <strong>متلازمة</strong><strong> </strong><strong>بروغادا</strong> (اضطراب وراثي يؤثر على القلب)، أو مشاكل أخرى بالقلب.</p><p dir="RTL">&middot;</p><p dir="RTL">إذا حصل لك أياً مما سبق:</p><p dir="RTL"><strong>أخبر طبيبك، قد يقرر خفض الجرعة، أو أن لاميكتال غير مناسب لك</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>حالات يجب التأكد منها</strong></p><p dir="RTL"><strong>معلومات مهمة عن تفاعلات جلدية خطيرة محتملة</strong></p><p dir="RTL">عدد صغير من الناس الذين يستعلمون لاميكتال تصيبهم تفاعلات تحسسية أو تفاعلات جلدية خطيرة، والتي قد تتطور إلى مشاكل أكثر خطورة مثل الفشل العضوي إذا لم تتم معالجتهم. عليك أن تعرف الأعراض لتناول الحيطة وأنت تتناول لاميكتال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اقرأ وصف هذه الأعراض في القسم 4 ﺑﻬذه النشرة </strong>تحت عنوان &quot;تفاعل جلدي خطير محتمل&nbsp;&nbsp;&nbsp;&nbsp; &quot;</p><p dir="RTL"><br /><strong>مرض</strong><strong> </strong><strong>خطير</strong><strong> </strong><strong>يصيب</strong><strong> </strong><strong>الجهاز</strong><strong> </strong><strong>المناعي</strong><strong> (</strong><strong>داء</strong><strong> </strong><strong>البلعمة</strong><strong> </strong><strong>أو</strong><strong> &quot;</strong><strong>HLH</strong><strong>&quot;)</strong></p><p dir="RTL">مرض خطير يصيب الجهاز المناعي، ويتسبب في فرط نشاط العضو المسؤول عن مقاومة الأمراض بالجسم. وعلى الرغم من ندرة إصابة الأشخاص الذين يتناولون دواء لاميكتال بهذا المرض، إلا أنه قد يُشكل تهديدًا للحياة. إذا كان لديك أي من الأعراض المصاحبة، أبلغ طبيبك المعالج على الفور.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اقرأ وصف هذه الأعراض في القسم 4 من هذه النشرة تحت عنوان &quot;مرض خطير يصيب الجهاز المناعي&quot;.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أفكار إيذاء النفس أو الانتحار</strong></p><p dir="RTL">أدوية مضادات الصرع تستخدم لعلاج عدة حالات، بما فيها الصرع والاضطراب ثنائي القطب. هناك عدد قليل من التقارير عن سلوك انتحاري (بما فيها الأفكار الانتحارية والانتحار) في المرضى الذين يعالجون ﺑﺄدوية مضادات الصرع مثل لاميكتال. إذا راودتك هذه الأفكار في أي وقت، <strong>اتصل بطبيبك على الفور</strong><strong>.</strong></p><p dir="RTL">إذا كنت تتناول لاميكتال لمنع تقلبات المزاج الحادة، قد لا تستشعر المفعول الكامل إلا بعد عدة أسابيع. أحياناً، أعراض الاكتئاب والاضطراب ثنائي القطب قد تشمل إيذاء النفس أو الإقدام على الانتحار.</p><p dir="RTL">الخطر قد يكون أكبر:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند بدء العلاج أو تغيير الجرعة للمرضى المصابين (أو كانوا مصابين) ﺑﺄفكار إيذاء النفس أو الإقدام على الانتحار للشباب البالغين</p><p dir="RTL">إذا كنت مصاب ﺑﺄفكار أو تجربة مسببة للاكتئاب، أو إذا لاحظت أنك أسوأ أو إذا تطورت عندك أعراض جديدة عند استعمالك للاميكتال:</p><p dir="RTL"><strong>اتصل بطبيبك على الفور أو اذهب لأقرب مستشفى لطلب المساعدة</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد تجد أنه من المفيد أن تخبر أحد أفراد الأسرة أو مقدم الرعاية أو صديق مقرب </strong>أنه يمكنك أن تصبح مكتئب أو لديك تغيرات ملموسة في المزاج، واطلب منهم قراءة هذه النشرة .قد تطلب منهم ان يخبروك ما إذ ا كانوا قلقون بشأن حالة الاكتئاب لديك أو غيرها من التغييرات في السلوك الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا يعطى لاميكتال للأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عاماً لعلاج الاضطراب ثنائي القطب. الأدوية التي تستخدم لعلاج الاكتئاب والمشاكل العقلية الأخرى تزيد من احتمالية الأفكار الانتحارية والسلوك الانتحاري في الأطفال والمراهقين الذين أعمارهم أقل من ١٨ عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول لاميكتال للصرع</strong></p><p dir="RTL">النوﺑﺎت في بعض أنواع الصرع أحياناً قد تحدث أسوأ أو قد تحدث أكثر من المعتاد خلال استعمالك للاميكتال. بعض المرضى قد يكون مصاب بنوﺑﺎت صرع حادة، التي قد تسبب مشاكل صحية خطيرة.</p><p dir="RTL">إذا كانت نوﺑﺎت صرعك أكثر من المعتاد أو إذا أصبت بنوﺑﺎت صرع حادة اثناء استعمالك لاميكتال:</p><p dir="RTL">&larr;&nbsp; <strong>اتصل بطيبك في أقرب وقت</strong><strong> .</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى و لاميكتال</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى، </strong>إذا تناولت أي أدوية مؤخراً، أو بدأت ﺑﺎستخدام أدوية جديدة. هذا يشمل الأدوية بدون وصفة طبية.</p><p dir="RTL">بعض الأدوية تؤثر على طريقة عمل لاميكتال، أو تزيد من احتمالية حدوث آﺛﺎر جانبية لدى الأشخاص.</p><p dir="RTL">لاميكتال قد يؤثر على أيضاً على طريقة عمل الأدوية الأخرى. هذا يشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فنيتوين، پريميدون أو فينوﺑﺎربيتون</strong>، تُستعمل لعلاج <strong>الصرع</strong><strong> </strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريسبيريدون</strong>، يستخدم لعلاج <strong>المشاكل المرتبطة ﺑﺎلصحة العقلية</strong><strong> </strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ڤالبرويت </strong>و<strong>كارﺑﺎمازيبين</strong>. يستخدم لعلاج <strong>الصرع </strong>و<strong>المشاكل المرتبطة ﺑﺎلصحة العقلية</strong><strong> </strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين</strong>، هو <strong>مضاد حيوي</strong><strong> </strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لعلاج <strong>الاصابة بفيروس نقص المناعة المكتسب </strong>(مركب من لوبيناڤير وربتوناڤير أو أتازاناڤير وريتوناڤير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المنتجات</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الاستروجين مثل مستحضرات هرمونية لمنع الحمل </strong>(انظر في الأسفل<strong> ) ومستحضرات هرمونبية بديلة </strong>.(</p><p dir="RTL">&nbsp;&larr; <strong>أخبر طبيبك </strong>أو الصيدلي إذا كنت تتناول أياً مما سبق، أو إذا بدأت ﺑﺎستخدام أو أوقفت استخدام أياً مما سبق. طبيبك قد يقرر تعديل الجرعة الخاصة بك.</p><p dir="RTL"><strong>حبوب منع الحمل الهرمونية قد تؤثر على طريقة عمل لاميكتال</strong></p><p dir="RTL">طبيبك قد يقترح عليكِ أن تتناولي نوع محدد من حبوب منع الحمل الهرمونية، أو أن تستخدمي وسيلة منع حمل أخرى، مثل الواقي الذكري، غطاء واقي أو لولب. إذا كنتِ تتناولين حبوب منع الحمل الهرمونية، أو إذ ا كنتِ تخططين للبدأ بتناولها أو إيقافها:</p><p dir="RTL">&larr; <strong>تحدثي لطبيبك، </strong>سوف يناقش الطريقة المناسبة لمنع الحمل لك .</p><p dir="RTL"><strong>لاميكتال قد يؤثر أيضاً على عمل موانع الحمل الهرمونية</strong></p><p dir="RTL">إذ ا كنتِ تتناولين حبوب منع الحمل الهرمونية، لاميكتال قد يؤثر على طريقة عملها. إذا لاحظتِ أي تغيير في وتيرة الدورة الشهرية مثل نزف مفاجئ أو وجود دم بين الدورات:</p><p dir="RTL">&larr; <strong>أخبري طبيبك، </strong>قد تكون هذه إشارات على أن لاميكتال يؤثر على عمل حبوب منع الحمل الأخرى .</p><p dir="RTL"><strong>تحاليل المختبر</strong></p><p dir="RTL">لاميكتال قد يتعارض مع التحاليل المخبرية للكشف عن الأدوية الأخرى. إذا كنت تحتاج تحليل مخبري، أخبر طبيبك أو المستشفى أنك تتناول لاميكتال.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">(هل أنتِ حامل أو تخططين للحمل؟ من المعروف أن لاميكتال قد يسبب الأذى للجنين.</p><p dir="RTL">هل تُرضعين؟ يختلط لاميكتال بحليب الثدي وقد يسبب بعض الآثار الجانبية للرضيع. إذا كنتِ تُرضعين، فيُرجى مراقبة طفلك عن كثب تحسبًا لظهور بعض الأعراض مثل صعوبة التنفس أو نوبات توقف التنفس أو النعاس أو ضعف القدرة على الرضاعة. يُرجى الاتصال فورًا بمقدم خدمات الرعاية الصحية لطفلك حال ملاحة أي من هذه الأعراض. كما يُرجى مناقشة مقدم خدمات الرعاية الصحية حول أفضل السبل للرضاعة إذا كنتِ تتناولين لاميكتال)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&larr; <strong>أخبري طبيبك إذا كنتِ حامل، أو قد تكونين حامل، أو تخططين للحمل. </strong>قد تزيد إحتمالية حدوث شفة مشقوقة أو حنك مشقوق للمولود إذا تم تناول لاميكتال في الأشهر القليلة الأولى لبداية الحمل .</p><p dir="RTL">&larr; <strong>تحدثي إلى طبيبك إذا كنتِ تقومين ﺑﺎلرضاعة الطبيعية أو كنتِ تخططين لأن تقومي بذلك</strong><strong>.</strong></p><p dir="RTL">المواد الفعالة في لاميكتال تنتقل إلى حليب الثدي وقد تؤثر على طفلك. طبيبك سيقرر المضار والمنافع للرضاعة الطبيعية أثناء تناولك لاميكتال .</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">لاميكتال قد يسبب دوخة، دوار وازدواج الرؤية.</p><p dir="RTL">&larr;<strong>لا يجوز قيادة السيارات أو تشغيل الماكينات </strong>إلا إذا كنت متأكداً من عدم ﺗﺄثرك ﺑﺎلعقار .</p><p dir="RTL"><strong>إذا كنت مصاﺑﺎً ﺑﺎلصرع، يرجى مراجعة الطبيب بشأن قيادة السيارات واستعمال الماكينات</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تناول لاميكتال دائماً وفقاً لتعليمات الطبيب. يجب الرجوع إلى الطبيب أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الجرعة التي يجب تناولها</strong></p><p dir="RTL">الأمر قد يستغرق بعض الوقت لتحديد الجرعة المناسبة لك من لاميكتال. الجرعة التي تتناولها سوف تعتمد على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمرك ووزنك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول لاميكتال مع أدوية أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل ﺑﺎلكلى أو الكبد</p><p dir="RTL">الطبيب سوف يصف جرعة منخفضة لبدء العلاج، ثم سيقوم بزيادة الجرعة تدريجياً على مدى أسابيع قليلة حتى بلوغ الجرعة المناسبة لك <strong><em>(الجرعة المؤثرة)</em></strong>. <strong>لا يجوز أبداً تناول لاميكتال بجرعة أكبر مما أخبرك</strong> <strong>الطبيب به</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الصرع</strong></p><p dir="RTL"><strong>البالغين والمراهقين فوق ١٣ سنة</strong><strong>:</strong></p><p dir="RTL">الجرعة المعتادة الفعالة من لاميكتال هي بين ١٠٠ ملجم إلى ٧٠٠ ملجم كل يوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال ( ٢ إلى ١٢ سنة)</strong><strong>:</strong></p><p dir="RTL">الجرعة الفعالة المعتادة تعتمد على وزن الجسم- عادة بين ١ملجم إلى ١٠ ملجم لكل كيلوجرام من وزن الطفل، بحد أقصى ٤٠٠ ملجم يوميا.</p><p dir="RTL">لاينصح ﺑﺎستخدام لاميكتال للأطفال في عمر أقل من سنتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاضطراب ثنائي القطب</strong></p><p dir="RTL"><strong>البالغين أكبر من ١٨ سنة فأكثر</strong><strong>:</strong></p><p dir="RTL">الجرعة الفعالة المعتادة هي بين ١٠٠ ملجم إلى ٤٠٠ ملجم يومياً.</p><p dir="RTL"><strong>الأطفال والمراهقين بعمر ١٨ سنة فأصغر</strong><strong>:</strong></p><p dir="RTL">لاينصح ﺑﺎستخدام لاميكتال للأطفال والمراهقين الذين هم أقل من ١٨ عاماً.</p><p dir="RTL"><strong>كيفية الاستخدام</strong></p><p dir="RTL">تناول جرعتك من لاميكتال مرة أو مرتين يومياً، كما نصحك الطبيب. يمكن تناوله مع أو بدون طعام.&nbsp; يمكن أيضاً أن ينصحك طبيبك ﺑﺄن تبدأ أو توقف الأدوية الأخرى، تبعاً لحالتك التي تعالج منها وكيفية استجابتك للعلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يجب بلع كامل القرص. </strong>لاتكسر ،تمضغ أو تحطم القرص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دائماً خذ الجرعة كاملة </strong>التي وصفها لك الطبيب. لايجوز أن تتناول جزء من القرص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تتناول جرعة واحدة من لاميكتال</strong></p><p dir="RTL">تناول الجرعة فور تذكرها ماعدا إذا كان متبقي على الجرعة التالية أقل من ٤ ساعات، في هذه الحالة تجاهل الجرعة المنسية وخذ جرعتك التالية في وقتها المعتاد.</p><p dir="RTL">&larr;<strong>لا تتناول ضعف الجرعة لكي تعوض الجرعة المنسية</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تتناول عدة جرعات من لاميكتال</strong></p><p dir="RTL">&larr;<strong>اسأل طبيبك طلباً للنصيحة لتعرف كيف تستطيع البدء ﺑﺎستخدام العقار من جديد، </strong>حتى لو لم تتوقف إلا لأيام قليلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت لاميكتال أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت لاميكتال أكثر مما ينبغي، قد تكون <strong>أكثر عرضة لحدوث أعراض جانبية خطيرة والتي قد تؤدي إلى الوفاة</strong>.</p><p dir="RTL">أعراض جانبية محتملة إذا تناولت كمية كبيرة جداً من لاميكتال وتشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة بحركة العين لا يمكن التحكم ﺑﻬا (رأرأة (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حماقة وفقدان التناسق، مما يؤثر على التوازن (ترنح (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو فقدان الوعي، نوﺑﺎت (تشنجات) أو غيبوبة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية كبيرة جداً اتصل بطبيبك أو اذهب لأقرب قسم طوارئ مستشفى على الفور. </strong>إذا كنت تستطيع، أظهر لهم علبة لاميكتال.</p><p dir="RTL"><strong>لاتوقف لاميكتال بدون مشورة</strong></p><p dir="RTL">تناول لاميكتال طالما نصحك طبيبك بذلك. لاتوقف تناول الدواء إلا إذا نصحك طبيبك بذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كنت تتناول لاميكتال كعلاج للصرع</strong></p><p dir="RTL">لإيقاف استعمال لاميكتال، من المهم أن تنقص الجرعة تدريجيا، لحوالي أسبوعين. إذا توقفت فجأة عن استعمال لاميكتال، قد يعود لك الصرع وقد يكون أسوأ.</p><p dir="RTL">&larr; <strong>تحدث لطبيبك قبل ايقاف استعمال لاميكتال</strong> .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كنت تستخدم لاميكتال لعلاج الاضطراب ثنائي القطب</strong></p><p dir="RTL">إذا كنت تتناول لاميكتال لعلاج تقلبات المزاج الحادة، قد لا يحدث التأثير الكامل إلا بعد عدة أسابيع.</p><p dir="RTL">إذا توقفت عن استعمال لاميكتال، جرعتك لا تحتاج لأن تخفض تدريجيا. لكن يظل يجب عليك أن تتحدث إلى طبيبك أولا، إذا كنت تريد ايقاف استعمال لاميكتال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كشأن كافة الأدوية، لاميكتال قد يسبب أعراضاً جانبية محتملة، إلا أنها لا تصيب كل فرد.</p><p dir="RTL"><strong>حالات تحتاج للحذر منها:</strong></p><p dir="RTL"><strong>تفاعل جلدي خطير محتمل</strong></p><p dir="RTL">عدد قليل من الأشخاص الذين يتناولون لاميكتال يصابون بحساسية أو تفاعلات جلدية خطيرة محتملة، التي قد تتطور لمشاكل إذا لم تعالج. الحساسية الشديدة نادرة (قد تصيب حتى فرد واحد من كل ١٠٠٠ فرد)</p><p dir="RTL">هذه الأعراض يزيد احتمالية حدوثها خلال الأشهر القليلة الأولى من العلاج بلاميكتال، خاصة إذا كانت الجرعة عالية جداً او إذا تمت زيادة الجرعة بسرعة جداً، أو إذا تم تناول لاميكتال مع دواء يسمى ڤالبرويت. تفاعلات جلدية خطيرة شائعة أكثر في الأطفال. أعراض تفاعلات الحساسية تشمل:</p><p dir="RTL"><strong>طفح جلدي أو احمرار</strong>، الذي قد يتطور إلى تفاعلات جلدية خطيرة وتشمل طفح جلدي منتشر مع بثور وتقشر الجلد، خاصة حول الفم، الأنف، العيون والأعضاء التناسلية (حمامى متعددة الأشكال ، متلازمة ستيفنز-جونز تقشر أنسجة البشرة الميتة التسممي (</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التهاب الفم أو العيون</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع الحرارة </strong>(حمى)، أعراض شبيهة ﺑﺎلانفلونزا أو نعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انتفاخ حول العين</strong>، <strong>أو انتفاخ الغدد </strong>في رقبتك، الحمرة الإبطية أو الأربية</p><p dir="RTL"><strong>في حالات عديدة</strong>، هذه الأعراض ستكون علامات لآﺛﺎر جانبية أقل خطورة. <strong>لكن يجب عليك أن تحذر من خطورة محتملة وممكن أن تتطور لمشاكل أكثر خطورة</strong>، مثل الفشل العضوي (فشل الكلى<strong> </strong>والكبد) واضطراﺑﺎت خطيرة في تخثر الدم من الممكن أن تسبب تكدم أو نزف غير متوقع (تخثر وريدي<strong> </strong>منتثر) . هذه الحالات نادرة جداً (حتى فرد واحد من كل ١٠٫٠٠٠ فرد).</p><p dir="RTL">&larr; <strong>اتصل بطبيبك على الفور </strong>إذا كنت تعاني من أي من هذه الأعراض .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرض خطير يصيب الجهاز المناعي (داء البلعمة</strong>)</p><p dir="RTL">مرض خطير يصيب الجهاز المناعي حيث تم الكشف عن الإصابة به عند تناول دواء &quot;لاميكتال&quot;، ويتسبب في فرط نشاط العضو المسؤول عن مقاومة الأمراض بالجسم. وعلى الرغم من ندرة إصابة الأشخاص بهذا المرض <strong>(حيث تصل إلى 1 من كل 10000</strong> شخص<strong>)</strong>، إلا أنه قد يُشكل تهديدًا للحياة، لذلك من المهم أن تعرف الأعراض التي تساهم في اكتشاف المرض. وتشمل الأعراض ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في درجة الحرارة (حمى)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في المشي أو الرؤية، والإصابة بنوبات سواءً حدثت لأول مرة أو تحدث في كثير من الأحيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الكبد و/أو الطحال مع وجع و/أو ألم عند اللمس في المنطقة باتجاه الجزء العلوي من المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اصفرار الجلد و/أو العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم الغدد في العنق والإبط و/أو الفخذ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالنزيف و/أو الكدمات بسهولة أكبر؛ وشحوب الوجه، والشعور بالتعب.</p><p dir="RTL">في معظم الحالات، قد تكون هذه الأعراض علامات على آثار جانبية أقل خطورة، ولكن يجب أن تدرك أنها قد تكون علامات على حالة يمكن أن تكون خطيرة إذا لم تُكتشف مبكرًا.</p><p dir="RTL"><strong>􀊮</strong><strong> </strong>&larr;<strong>اتصل بطبيبك على الفور إذا لاحظت أياً من هذه الأعراض.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الكبد ومشاكل الدم</strong></p><p dir="RTL">تم تسجيل حالات نادرة أثناء استعمال لاميكتال (حتى فرد من كل ١٫٠٠٠ فرد). الأعراض التالية قد تكون مصحوبة بشعور عام ﺑﺎلمرض أو أنك على غير ما يرام:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن و/أو التألم ﺑﺎللمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور ﺑﺄنك متعب جدا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف أو تكدم غير متوقع، او تحول الأصابع للون الازرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق ، أو عدوى أكثر (مثل البرد) أكثر من المعتاد</p><p dir="RTL"><strong>􀊮</strong><strong> </strong>&larr;<strong>اتصل بطبيبك على الفور إذا لاحظت أياً من هذه الأعراض. </strong>طبيبك قد يقرر عمل<strong> </strong>اختبارات لكبدك، كليتيك أو الدم، وقد يخبرك ﺑﺄن توقف استخدام لاميكتال .</p><p dir="RTL"><strong>ازدياد سوء نوبات الصرع</strong></p><p dir="RTL">في الأشخاص <strong>المصابين ﺑﺎلصرع</strong>: <strong>النوﺑﺎت تحدث بشكل أكثر</strong>. هذه نادرة جداً <strong>(حتى فرد واحد من كل ١٠٫٠٠٠ فرد) </strong>من الذين يستعملون لاميكتال.</p><p dir="RTL">&larr;<strong>اخبر طبيبك ﺑﺄقرب وقت </strong>إذا حدثت أي من الأعراض السابقة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية شائعة جداً </strong>(تصيب <strong>أكثر من فرد واحد من كل ١٠ أفراد</strong>):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور ﺑﺎلدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور ﺑﺎلنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حماقة وفقدان التناسق، مما يؤثر على التوازن (ترنح (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيم الرؤية أو ازدواج الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور ﺑﺎلمرض (غثيان) أو المرض (قيء (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة </strong>(تصيب <strong>حتى فرد واحد من كل ١٠ أفراد</strong>):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدائية، سرعة التهيج أو التوتر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (أرق (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور ﺑﺎلنعاس أو التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلاجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة بحركة العين لا يمكن التحكم ﺑﻬا (رأرأة (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر، المفاصل أو أي مكان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة </strong>(تصيب <strong>حتى فرد واحد من كل ١٠٠٠ فرد</strong>):</p><p dir="RTL">&middot; الطفح الجلدي، والذي قد يتقرّح ويشبه الأجزاء الناتئة الصغيرة (بقع سوداء متمركزة تحيط بها مساحة شاحبة، مع وجود حلقة داكنة حول الأطراف - حمامى متعددة الأشكال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي خطير (متلازمة ستيفنز-جونز) انظر أيضاً المعلومات في بداية قسم ٤</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة ﺑﺎلعين مع افرازات و قشور في الرموش (التهاب الملتحمة (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجموعة من الآﺛﺎر الجانبية معاً تشمل: صداع، حمى، غثيان، قيء، تيبس الرقبة، حكة، حساسية غير معتادة للضوء، آلام في العضلات، رعشة، تشوش ودوخة. قد تحدث بسبب التهاب الغشاء الذي يغطي الدماغ والحبل الشوكي (التهاب السحايا (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر الغير طبيعي أو ترقق (ثعلبة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة جداً </strong>(قد تصيب <strong>حتى فرد واحد من كل ١٠٫٠٠٠ فرد</strong>):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار مصحوب ببثرات وتقشر الجلد بمساحة كبيرة من الجسم (تقشر أنسجة البشرة الميتة التسممي). انظر المعلومات في بداية قسم ٤</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل متعدد الأعضاء (فشل الكلى والكبد) واضطراﺑﺎت خطيرة في تخثر الدم من الممكن أن تسبب تكدم أو نزف غير متوقع (تخثر وريدي منتثر). انظر المعلومات في بداية قسم ٤</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض خطير يصيب الجهاز المناعي (داء البلعمة أو <strong>&quot;</strong><strong>HLH</strong><strong>&quot;</strong><strong>&quot;)، </strong>انظر أيضًا المعلومات الواردة في بداية القسم 4.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه (ورم) أو تورم الغدد في العنق، الإبط أو الأربية (تضخم العقد اللامفاوية). انظر المعلومات في بداية قسم ٤</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بما في ذلك العقد أو التصبغات الحمراء على الجلد (الورم اللمفاوي الكاذب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة (حمى)، انظر أيضاً المعلومات في بداية القسم ٤</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأشخاص المصابين ﺑﺎلصرع، النوﺑﺎت تحدث بشكل أكبر، انظر أيضاً المعلومات في بداية القسم ٤</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلية (التهاب الكلية الخلالي)، والذي قد يحدث بالتزامن مع التهاب العين (التهاب القزحية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات الجسم اللاإرادية (داء العرات)، انقباضات لا إرادية في العضلات تؤثر على العيون، الرأس والجذع (كنع رقصي)، أو حركات جسم لا إرادية أخرى مثل رأرأة، ارتعاش أو تيبس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور ﺑﺎلتذبذب أو عدم الإتزان عند الحركة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش أو هياج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء غير موجودة (هلوسة (</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأشخاص المصابين بمرض ﺑﺎركنسون، الأعراض تكون أسوأ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة (الاعراض قد تشمل: ألم في الظهر أو المفاصل أحياناً قد يكون مصحوب بحمى و/أو توعك عام في الصحة (</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية نادرة جداً قد تظهر في اختبارات الدم</strong></p><p dir="RTL">قد تصيب <strong>حتى فرد من كل ١٠٫٠٠٠ فرد</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في وظيفة الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدم الحمراء (فقر الدم المنجلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدم البيضاء (قلة العدلات، قلة الكريات البيضاء، ندرة المحببات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد الصفائح الدموية التي تساعد في إيقاف نزيف الدم (قلة الصفيحات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص العدد في كل هذه الأنواع من الخلايا (قلة الكريات الشاملة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في نخاع العظام يسمى فقر الدم اللاتنسجي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الأجسام المضادة (الغلوبولين المناعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&larr;</strong><strong>أخبر طبيبك أو الصيدلي </strong>إذا كان أي من الأعراض الجانبية المذكورة سابقاً أصبحت<strong> شديدة أو مزعجة، </strong>أو إذا لاحظت أي أعراض جانبية غير مذكورة في النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2.&nbsp; </strong><strong>طريقة تخزين لاميكتال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ بعيداً عن متناول ونظر الأطفال</strong><strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز استعمال لاميكتال بعد ﺗﺎريخ انتهاء الصلاحية المبين على العبوة بعد كلمة &quot;Exp&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخزن لاميكتال تحت ٣٠&deg;م. يحفظ جافاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بوقف تناول لاميكتال، فمن المهم إعادة أي كمية متبقية إلى الصيدلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز التخلص من الأدوية في مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد على وقاية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي لاميكتال</strong></p><p dir="RTL">المادة الفعالة هي لاموتريجين.</p><p dir="RTL">كل قرص يحتوي على 25، 50 أو ١٠٠ ملجم لاموتريجين.</p><p dir="RTL">مكونات أخرى غير فعالة:</p><p dir="RTL">سيليولوز دقيق التبلور، بوفيدون، جلايكولات نشا الصوديوم، أوكسيد الحديد الأصفر (172)، ستياريت الماغنيسيوم.</p><p dir="RTL">أقراص لاميكتال تحتوي على لاكتوز مونوهيدريت. المرضى الذين يعانون من مشاكل وراثية نادرة تتعلق بتحمل الجلاكتوز، خلل اللاكتوز اللابي أو سوء امتصاص جلوكوز-جلاكتوز عليهم تجنب تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص لاميكتال ٢٥ ملجم هي أقراص مستديرة الشكل، ذات لون بني مصفر شاحب، متعددة الأوجه على أحد جانبيها محفور &quot;GSEC7&quot;، والجانب الآخر &quot;25&quot;</p><p dir="RTL">أقراص لاميكتال 50 ملجم هي أقراص مستديرة الشكل، ذات لون بني مصفر شاحب، متعددة الأوجه على أحد جانبيها محفور &quot;GSEE1&quot;، والجانب الآخر &quot;50&quot;</p><p dir="RTL">أقراص لاميكتال 100 ملجم هي أقراص مستديرة الشكل، ذات لون بني مصفر شاحب، متعددة الأوجه على أحد جانبيها محفور &quot;GSEE5&quot;، والجانب الآخر &quot;100&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تسوق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>لاميكتال</em> علامة تجارية مملوكة أو مرخصة لمجموعة شركات .GSK</p><p dir="RTL">&copy; 2024 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع</strong><strong>:</strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>تعبئة</strong><strong>:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL"><strong>الشركة المالكة لرخصة التسويق</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL">العنوان: صندوق بريد ٢٢٦١٧ ، جدة ٢١٤١٦ ، المملكة العربية السعودية</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666-12-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: 9882-904-56-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: Ugcc.medinfo@gsk.comU</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:roundrect id="AutoShape_x0020_5"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:1.05pt;margin-top:2.6pt;width:481.9pt;height:285.35pt;z-index:251662336;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="2.5pt">
 <v:shadow color="#868686"/>
 <v:textbox inset=",0,,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><b><span lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:
    12.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>للإبلاغ</span></b><b><span
    lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:
    "Traditional Arabic",serif'> </span></b><b><span lang=AR-EG
    style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>عن</span></b><b><span lang=AR-EG style='font-size:
    14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif'> </span></b><b><span
    lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-EG'>أية</span></b><b><span
    lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:
    "Traditional Arabic",serif'> </span></b><b><span lang=AR-EG
    style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>آثار</span></b><b><span lang=AR-EG
    style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif'>
    </span></b><b><span lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:
    12.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>جانبية</span></b><b><span
    style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif'>:</span></b><b><span
    dir=LTR style='font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><b><i><span lang=AR-EG style='font-size:14.0pt;
    mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>المملكة</span></i></b><b><i><span lang=AR-EG
    style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif'>
    </span></i></b><b><i><span lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:
    12.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>العربية</span></i></b><b><i><span
    lang=AR-EG style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:
    "Traditional Arabic",serif'> </span></i></b><b><i><span lang=AR-EG
    style='font-size:14.0pt;mso-ansi-font-size:12.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>السعودية</span></i></b><b><i><span dir=LTR
    style='font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></i></b></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=RTL></span><b><span style='font-size:12.0pt;
    font-family:"Traditional Arabic",serif'><span dir=RTL></span>- </span></b><b><span
    lang=AR-SA style='font-size:12.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-SA'>المركز القومي للتيقظ والسلامة الدوائية </span></b><span
    dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
    font-family:"Traditional Arabic",serif;mso-ansi-language:EN-US;mso-bidi-language:
    AR-SA'><span dir=LTR></span>(NPC)<o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    mso-pagination:widow-orphan;mso-list:l4 level1 lfo1;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>الاتصال
    بالرقم الموحد</span><span lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'>:
    19999</span><span style='font-size:12.0pt;mso-ansi-font-size:11.0pt;
    font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    mso-pagination:widow-orphan;mso-list:l4 level1 lfo1;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>البريد</span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif'> </span><span lang=AR-EG style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>الإلكتروني</span><span style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>:</span><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;mso-bidi-language:AR-SA'> </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span dir=LTR style='mso-bidi-font-size:
    12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
    mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'>npc.drug@sfda.gov.sa</span></a><span
    dir=LTR style='mso-bidi-font-size:12.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;line-height:115%;mso-pagination:widow-orphan;mso-list:
    l1 level1 lfo3;tab-stops:list .5in;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span lang=EN-US
    style='font-size:12.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:EN-US;mso-fareast-language:
    EN-US;mso-bidi-language:AR-SA'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;line-height:115%;font-family:"Traditional Arabic",serif;mso-bidi-language:
    AR-EG'>الموقع</span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;line-height:115%;font-family:"Traditional Arabic",serif'> </span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;line-height:
    115%;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>الإلكتروني</span><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;line-height:115%;
    font-family:"Traditional Arabic",serif'>:</span><span class=MsoHyperlink><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;line-height:115%'> </span></span><a
    href="https://ade.sfda.gov.sa/"><span lang=EN-US dir=LTR style='font-size:
    12.0pt;line-height:115%;font-family:"Times New Roman",serif;mso-fareast-font-family:
    +mn-ea;mso-bidi-font-family:+mn-cs;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>https://ade.sfda.gov.sa</span></a><span
    lang=EN-US dir=LTR style='font-size:12.0pt;line-height:115%;font-family:
    "Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;mso-pagination:widow-orphan;
    text-autospace:ideograph-numeric ideograph-other;direction:rtl;unicode-bidi:
    embed'><span style='mso-field-code:HYPERLINK'></span><b><span dir=LTR
    style='font-size:5.0pt;mso-bidi-font-size:6.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=RTL></span><b><span style='font-size:14.0pt;
    font-family:"Traditional Arabic",serif'><span dir=RTL></span>- </span></b><b><span
    lang=AR-EG style='font-size:14.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>جلاكسو</span></b><b><span lang=AR-EG
    style='font-size:14.0pt;font-family:"Traditional Arabic",serif'> </span></b><b><span
    lang=AR-EG style='font-size:14.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>سميث</span></b><b><span lang=AR-EG
    style='font-size:14.0pt;font-family:"Traditional Arabic",serif'> </span></b><b><span
    lang=AR-EG style='font-size:14.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>كلاين</span></b><b><span style='font-size:14.0pt;
    font-family:"Traditional Arabic",serif'> – </span></b><b><span lang=AR-EG
    style='font-size:14.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:
    AR-EG'>المكتب</span></b><b><span lang=AR-EG style='font-size:14.0pt;
    font-family:"Traditional Arabic",serif'> </span></b><b><span lang=AR-EG
    style='font-size:14.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:
    AR-EG'>الرئيسي،</span></b><b><span lang=AR-EG style='font-size:14.0pt;
    font-family:"Traditional Arabic",serif'> </span></b><b><span lang=AR-EG
    style='font-size:14.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:
    AR-EG'>جدة</span></b><b><span style='font-size:14.0pt;font-family:"Traditional Arabic",serif'>.</span></b><b><span
    dir=LTR style='font-size:14.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;mso-pagination:widow-orphan;mso-list:l4 level1 lfo1;
    tab-stops:right 13.5pt;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span style='font-size:12.0pt;mso-ansi-font-size:11.0pt;
    font-family:"Traditional Arabic",serif'>هاتف: </span><span lang=AR-EG
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>6536666 (12) 966 +</span><span style='font-size:
    12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;mso-pagination:widow-orphan;mso-list:l4 level1 lfo1;
    tab-stops:right 13.5pt;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-bidi-language:AR-EG'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span style='font-size:
    12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>جوال:
    </span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;
    font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>9882-904-56-966
    +<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;mso-pagination:widow-orphan;mso-list:l0 level1 lfo4;
    tab-stops:list .5in;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span lang=EN-US
    style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:
    EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-EG
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>البريد</span><span lang=AR-EG style='font-size:
    12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'> </span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-EG'>الإلكتروني</span><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>
    : </span><u><span dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:+mn-cs;
    color:blue;mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:
    AR-SA'>s</span></u><span dir=LTR><a href="mailto:Saudi.safety@gsk.com"><span
    style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
    "Times New Roman";mso-bidi-font-family:+mn-cs;mso-font-kerning:12.0pt;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>audi.safety@gsk.com</span></a></span><span
    lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:10.0pt;font-family:
    "Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;mso-pagination:widow-orphan;mso-list:l2 level1 lfo5;
    tab-stops:list .5in;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span lang=EN-US
    style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:
    EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-EG
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>الموقع</span><span lang=AR-EG style='font-size:
    12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'> </span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-EG'>الإلكتروني</span><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>:
    </span><u><span dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:+mn-cs;
    color:blue;mso-font-kerning:12.0pt;mso-fareast-language:EN-US;mso-bidi-language:
    AR-SA'>https://gskpro.com/en-sa/ </span></u><span lang=AR-SA
    style='font-size:12.0pt;mso-ansi-font-size:10.0pt;font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;mso-pagination:widow-orphan;mso-list:l4 level1 lfo1;
    tab-stops:right 13.5pt;text-autospace:ideograph-numeric ideograph-other;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>ص</span><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>.</span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-EG'>ب</span><span
    style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>
    55850</span><span lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:
    11.0pt;font-family:"Traditional Arabic",serif;mso-bidi-language:AR-EG'>،</span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif'> </span><span lang=AR-EG style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>جدة</span><span style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'> 21544</span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-EG'>،</span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif'> </span><span lang=AR-EG style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>المملكة</span><span lang=AR-EG style='font-size:
    12.0pt;mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'> </span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-EG'>العربية</span><span
    lang=AR-EG style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:
    "Traditional Arabic",serif'> </span><span lang=AR-EG style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif;
    mso-bidi-language:AR-EG'>السعودية</span><span style='font-size:12.0pt;
    mso-ansi-font-size:11.0pt;font-family:"Traditional Arabic",serif'>.</span><span
    dir=LTR style='mso-bidi-font-size:12.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="649" height="387" alt="Rectangle: Rounded Corners: للإبلاغ عن أية آثار جانبية:
المملكة العربية السعودية
- المركز القومي للتيقظ والسلامة الدوائية (NPC)
•	الاتصال بالرقم الموحد: 19999
•	البريد الإلكتروني: npc.drug@sfda.gov.sa
•	الموقع الإلكتروني: https://ade.sfda.gov.sa

- جلاكسو سميث كلاين – المكتب الرئيسي، جدة.
•	هاتف: 6536666 (12) 966 +
•	جوال: 9882-904-56-966 +
•	البريد الإلكتروني : saudi.safety@gsk.com
•	الموقع الإلكتروني: https://gskpro.com/en-sa/ 
•	ص.ب 55850، جدة 21544، المملكة العربية السعودية.
" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            إصدار رقم: GDS53 
ﺗﺎريخ الإصدار: 08 يوليو 2024

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamotrigine 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LAMICTAL 25, 50 and 100 mg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamictal Tablets 25 mg are pale-yellowish brown, multifaceted super elliptical flat tablet, engraved “GSEC7” on one side and “25” on the other.
Lamictal Tablets 50 mg are pale-yellowish brown, multifaceted super elliptical flat tablet, engraved “GSEE1” on one side and “50” on the other.
Lamictal Tablets 100 mg are pale-yellowish brown, multifaceted super elliptical flat tablet, engraved “GSEE5” on one side and “100” on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; EPILEPSY<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e2c3d3d1-4dd8-43b5-944c-84f55016b51f \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults and adolescents (over 12 years of age)</strong></p><p><em>LAMICTAL </em>is indicated for use as adjunctive or monotherapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children (2 to 12 years of age)<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_94b45fef-02fa-4d78-8f30-db1236dab2cf \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><em>LAMICTAL </em>is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.</p><p>&nbsp;</p><p>After epileptic control has been achieved during adjunctive therapy, concomitant anti- epileptic drugs (AEDs) may be withdrawn and patients continued on <em>LAMICTAL </em>monotherapy.</p><p>&nbsp;</p><p><em>LAMICTAL </em>is indicated as monotherapy in the treatment of typical absence seizures.</p><p>&nbsp;</p><p>BIPOLAR DISORDER<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_a961b2e0-c45a-4ccc-b41d-3c1059a7d354 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults (18 years of age and over)</strong></p><p><em>LAMICTAL </em>is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>LAMICTAL </em>tablets should be swallowed whole, and should not be chewed or crushed.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>LAMICTAL </em>dispersible/chewable tablets may be chewed, dispersed in a small volume of water (at least enough to cover the whole tablet) or swallowed whole with a little water.</p><p>&nbsp;</p><p>If a calculated dose of <em>LAMICTAL, </em>e.g. for use in children (epilepsy only) or patients with hepatic impairment, cannot be divided into multiple lower strength tablets, the dose to be administered is that equal to the nearest lower strength of whole tablets.</p><p>&nbsp;</p><p><strong>Restarting Therapy</strong></p><p><strong>&nbsp;</strong></p><p>Prescribers should assess the need for escalation to maintenance dose when restarting <em>LAMICTAL </em>in patients who have discontinued <em>LAMICTAL </em>for any reason, since the risk of serious rash is associated with high initial doses and exceeding the recommended dose escalation for <em>LAMICTAL (see Warnings and Precautions)</em>. The greater the interval of time since the previous dose, the more consideration should be given to escalation to the maintenance dose. When the interval since discontinuing <em>LAMICTAL </em>exceeds five half- lives <em>(see Pharmacokinetics), LAMICTAL </em>should generally be escalated to the maintenance dose according to the appropriate schedule.</p><p>It is recommended that <em>LAMICTAL </em>not be restarted in patients who have discontinued due to rash associated with prior treatment with <em>LAMICTAL </em>unless the potential benefit clearly outweighs the risk.</p><p>&nbsp;</p><p>&nbsp;</p><p>EPILEPSY<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_b5fad6ee-2517-403a-9bb6-169d66e5924c \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>When concomitant anti-epileptic drugs are withdrawn to achieve <em>LAMICTAL </em>monotherapy or other AEDs are added-on to treatment regimes containing lamotrigine, consideration should be given to the effect this may have on lamotrigine pharmacokinetics (<em>see Interactions</em>).</p><p>&nbsp;</p><p><u>Dosage in Epilepsy Monotherapy</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4b53cb12-6cd7-4189-a0d2-a079e0279bd7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults and adolescents (over 12 years of age) (see Table 1)</strong></p><p>The initial <em>LAMICTAL </em>dose in monotherapy is 25 mg once a day for two weeks, followed by 50 mg once a day for two weeks. Thereafter, the dose should be increased by a maximum of 50 to 100 mg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 100 to 200 mg/day given once a day or as two divided doses. Some patients have required 500 mg/day of <em>LAMICTAL </em>to achieve the desired response.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children (2 to 12 years of age) (see Table 2)<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ee9da2fe-18cf-4720-b413-a9c2e94541ce \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>The initial <em>LAMICTAL </em>dose in monotherapy in typical absence seizures is 0.3 mg/kg bodyweight/day given once a day or in two divided doses for two weeks, followed by</p><p>0.6 mg/kg/day given once a day or in two divided doses for two weeks. Thereafter, the dose should be increased by a maximum of 0.6 mg/kg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 1 to 10 mg/kg/day given once a day or in two divided doses, although some patients with typical absence seizures have required higher doses to achieve the desired response.</p><p>&nbsp;</p><p>Because of a risk of rash, the initial dose and subsequent dose escalation should not be exceeded (<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p><u>Dosage in Epilepsy Add-On Therapy</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2c67b86a-3bff-4d56-b1b0-c3d880c5bd99 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults and adolescents (over 12 years of age) (see Table 1)</strong></p><p>In patients taking valproate with/without any other AED, the initial <em>LAMICTAL </em>dose is 25 mg every alternate day for two weeks, followed by 25 mg once a day for two weeks. Thereafter, the dose should be increased by a maximum of 25 to 50 mg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 100 to 200 mg/day given once a day or in two divided doses.</p><p>&nbsp;</p><p>In those patients taking concomitant AEDs or other medications (<em>see Interactions</em>) that induce lamotrigine glucuronidation with/without other AEDs (except valproate), the initial <em>LAMICTAL </em>dose is 50 mg once a day for two weeks, followed by 100 mg/day given in two divided doses for two weeks. Thereafter, the dose should be increased by a maximum of 100 mg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 200 to 400 mg/day given in two divided doses. Some patients have required 700 mg/day of <em>LAMICTAL </em>to achieve the desired response.</p><p>&nbsp;</p><p>In those patients taking other medications that do not significantly inhibit or induce lamotrigine glucuronidation (<em>see Interactions</em>), the initial <em>LAMICTAL </em>dose is 25 mg once a day for two weeks, followed by 50 mg once a day for two weeks. Thereafter, the dose should be increased by a maximum of 50 to 100 mg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve an optimal response is 100 to 200 mg/day given once a day or as two divided doses.</p><p>&nbsp;</p><p>Table 1: Recommended treatment regimen in EPILEPSY for adults and adolescents over 12 years of age<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5fa2d21d-35ca-4826-83cf-fa9e060cfd44 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Treatment regimen</strong></p></td><td style="vertical-align:top"><p><strong>Weeks 1-2</strong></p></td><td style="vertical-align:top"><p><strong>Weeks 3-4</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance Dose</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Monotherapy</p></td><td style="vertical-align:top"><p>25&nbsp; mg (once a day)</p></td><td style="vertical-align:top"><p>50&nbsp; mg (once a day)</p></td><td style="vertical-align:top"><p>100 &ndash; 200 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p><p><strong>&nbsp;</strong></p><p>To achieve maintenance, doses may be increased by 50 &ndash;</p><p>100 mg every one to two weeks</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Add-on therapy with valproate regardless of any concomitant medications</p></td><td style="vertical-align:top"><p>12.5 mg</p><p><strong>&nbsp;</strong></p><p>(given 25 mg alternate days)</p></td><td style="vertical-align:top"><p>25&nbsp; mg (once a day)</p></td><td style="vertical-align:top"><p>100 &ndash; 200 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p><p><strong>&nbsp;</strong></p><p>To achieve maintenance, doses may be increased by 25 &ndash; 50 mg every one to two weeks</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Add-on therapy without valproate</p></td><td style="vertical-align:top"><p>This dosage regimen should be used with:</p><p><strong>&nbsp;</strong></p><p>Phenytoin Carbamazepine Phenobarbitone Primidone</p><p><strong>&nbsp;</strong></p><p>Or with other inducers of lamotrigine glucuronidation (<em>see Interactions</em>)</p></td><td style="vertical-align:top"><p>50&nbsp; mg (once a day)</p></td><td style="vertical-align:top"><p>100 mg</p><p><strong>&nbsp;</strong></p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>200 &ndash; 400 mg</p><p><strong>&nbsp;</strong></p><p>(two divided doses)</p><p><strong>&nbsp;</strong></p><p>To achieve maintenance, doses may be increased by 100 mg every one to two weeks</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medications that do not significantly inhibit or induce lamotrigine glucuronidation (<em>see Interactions</em>)</p></td><td style="vertical-align:top"><p>25&nbsp; mg (once a day)</p></td><td style="vertical-align:top"><p>50&nbsp; mg (once a day)</p></td><td style="vertical-align:top"><p>100 &ndash; 200 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p><p><strong>&nbsp;</strong></p><p>To achieve maintenance, doses may be increased by 50 &ndash;</p><p>100 mg every one to two weeks</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>In patients taking AEDs where the pharmacokinetic interaction with <em>LAMICTAL </em>is currently not known (<em>see Interactions</em>), the treatment regimen as recommended for <em>LAMICTAL </em>with concurrent valproate should be used.</p></td></tr></tbody></table><p>Because of a risk of rash, the initial dose and subsequent dose escalation should not be exceeded (<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children (2 to 12 years of age) (see Table 2)<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7d1fd331-1df7-4c24-9519-bfe466b9b8ee \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>In patients taking valproate with/without any other AED, the initial <em>LAMICTAL </em>dose is</p><p>0.15 mg/kg bodyweight/day given once a day for two weeks, followed by 0.3 mg/kg/day once a day for two weeks. Thereafter, the dose should be increased by a maximum of</p><p>&nbsp;</p><p>0.3 mg/kg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 1 to 5 mg/kg/day given once a day or in two divided doses, with a maximum of 200 mg/day.</p><p>&nbsp;</p><p>In those patients taking concomitant AEDs or other medications (<em>see Interactions</em>) that induce lamotrigine glucuronidation with/without other AEDs (except valproate), the initial <em>LAMICTAL </em>dose is 0.6 mg/kg bodyweight/day given in two divided doses for two weeks, followed by 1.2 mg/kg/day given in two divided doses for two weeks. Thereafter, the dose should be increased by a maximum of 1.2 mg/kg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 5 to 15 mg/kg/day given once a day or<strong><em> </em></strong>in two divided doses, with a maximum of 400 mg/day.</p><p>&nbsp;</p><p>In patients taking other medications that do not significantly inhibit or induce lamotrigine glucuronidation (<em>see Interactions</em>), the initial <em>LAMICTAL </em>dose is 0.3 mg/kg bodyweight/day given once a day or in two divided doses for two weeks, followed by</p><p>0.6 mg/kg/day given once a day or in two divided doses for two weeks. Thereafter, the dose should be increased by a maximum of 0.6 mg/kg every one to two weeks until the optimal response is achieved. The usual maintenance dose to achieve optimal response is 1 to 10 mg/kg/day given once a day or in two divided doses, with a maximum of</p><p>200 mg/day.</p><p>&nbsp;</p><p>To ensure a therapeutic dose is maintained the weight of a child must be monitored and the dose reviewed as weight changes occur.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 2: Recommended treatment regimen in EPILEPSY for children aged 2-12 years (total daily dose in mg/kg bodyweight/day).**<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8078ba07-e4a0-4f58-8ff2-124c24549b08 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Treatment regimen</strong></p></td><td style="vertical-align:top"><p><strong>Weeks 1-2</strong></p></td><td style="vertical-align:top"><p><strong>Weeks 3-4</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance Dose</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>Monotherapy in typical absence seizures</p></td><td style="vertical-align:top"><p>0.3&nbsp;mg/kg (once a day or two divided doses)</p></td><td style="vertical-align:top"><p>0.6&nbsp;mg/kg (once a day or two divided doses)</p></td><td style="vertical-align:top"><p>0.6&nbsp;mg/kg increments every one to two weeks to achieve a maintenance dose of 1&nbsp;-&nbsp;10&nbsp;mg/kg (once a day or two divided doses) to a maximum of 200&nbsp;mg/day.</p></td></tr><tr><td colspan="2"><p>Add-on therapy with valproate regardless of any other concomitant medication</p></td><td style="vertical-align:top"><p>0.15&nbsp;mg/kg*</p><p>(once a day)</p></td><td style="vertical-align:top"><p>0.3&nbsp;mg/kg</p><p>(once a day)</p></td><td style="vertical-align:top"><p>0.3&nbsp;mg/kg increments every one to two weeks to achieve a maintenance dose of 1 &ndash; 5&nbsp;mg/kg (once a day or two divided doses) to a maximum of 200&nbsp;mg/day.</p></td></tr><tr><td rowspan="2"><p>Add-on therapy without valproate</p></td><td style="vertical-align:top"><p>This dosage regimen should be used with:</p><p>Phenytoin<br />Carbamazepine<br />Phenobarbitone<br />Primidone</p><p>Or with other inducers of lamotrigine glucuronidation (<em>see Interactions</em>)</p></td><td style="vertical-align:top"><p>0.6&nbsp;mg/kg</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>1.2&nbsp;mg/kg</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>1.2&nbsp;mg/kg increments every one to two weeks to achieve a maintenance dose of 5 &ndash; 15&nbsp;mg/kg (once a day or two divided doses) to a maximum of 400&nbsp;mg/day.</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medications that do not significantly<strong><em> </em></strong>inhibit or induce<strong> </strong>lamotrigine glucuronidation<strong> </strong>(<em>see Interactions</em>)</p></td><td style="vertical-align:top"><p>0.3&nbsp;mg/kg</p><p>(one or two divided doses)</p></td><td style="vertical-align:top"><p>0.6&nbsp;mg/kg</p><p>(one or two divided doses)</p></td><td style="vertical-align:top"><p>0.6 mg/kg increments every one to two weeks to achieve a maintenance dose of 1 &ndash; 10&nbsp;mg/kg (once a day or two divided doses) to a maximum of 200 mg/day.</p></td></tr><tr><td colspan="5"><p>In patients taking AEDs where the pharmacokinetic interaction with lamotrigine is currently not known (<em>see Interactions</em>), the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.</p></td></tr><tr><td colspan="5"><p>*(Where 5 mg tablets are the lowest strength available) If the calculated daily dose in patients taking valproate is between 2.5 to 5 mg, then 5 mg may be taken on alternate days for the first two weeks. If the calculated daily dose in patients taking valproate is less than 2.5 mg, then LAMICTAL should not be used.</p></td></tr></tbody></table><p>** If the calculated dose of LAMICTAL cannot be achieved using whole tablets, the dose should be rounded down to the nearest whole tablet.</p><p>&nbsp;</p><p>Because of a risk of rash, the initial dose and subsequent dose escalation should not be exceeded (see Warnings and Precautions).</p><p>&nbsp;</p><p>It is likely that patients aged two to six years will require a maintenance dose at the higher end of the recommended range.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Epilepsy Monotherapy and Add-On Therapy</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_6ebc5dc7-b9b2-485f-8539-82301c579d05 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children aged less than 2 years</strong></p><p>Lamotrigine has not been studied as monotherapy in children less than 2 years of age or as add-on therapy in children less than 1 month of age. The safety and efficacy of lamotrigine as add-on therapy of partial seizures in children aged 1 month to 2 years has not been established (<em>see Clinical Studies</em>). Therefore, <em>LAMICTAL </em>is not recommended in children less than 2 years of age.</p><p>&nbsp;</p><p>BIPOLAR DISORDER<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_84f2019a-35ea-4551-b24d-647840b959db \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults (18 years of age and over)</strong></p><p>Because of the risk of rash, the initial dose and subsequent dose escalation should not be exceeded (<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p><em>LAMICTAL </em>is recommended for use in bipolar patients at risk for a future depressive episode.</p><p>&nbsp;</p><p>The following transition regimen should be followed to prevent recurrence of depressive episodes. The transition regimen involves escalating the dose of <em>LAMICTAL </em>to a maintenance stabilisation dose over six weeks (see Table 3) after which other psychotropic and/or anti-epileptic drugs can be withdrawn, if clinically indicated (see Table 4).</p><p>&nbsp;</p><p>Adjunctive therapy should be considered for the prevention of manic episodes, as efficacy with <em>LAMICTAL </em>in mania has not been conclusively established.</p><p>&nbsp;</p><p>Table 3: Recommended dose escalation to the maintenance total daily stabilisation dose for adults (18 years of age and over) treated for BIPOLAR DISORDER<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_638f339c-f40c-4637-aee8-8ec350177a92 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Weeks 1-2</strong></p></td><td style="vertical-align:top"><p><strong>Weeks 3-4</strong></p></td><td style="vertical-align:top"><p><strong>Week 5</strong></p></td><td style="vertical-align:top"><p><strong>Target Stabilisation Dose (Week 6)**</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>a) Adjunct therapy with inhibitors of lamotrigine glucuronidation e.g. Valproate</strong></p></td><td style="vertical-align:top"><p>12.5 mg</p><p><strong>&nbsp;</strong></p><p>(given 25 mg alternate days)</p></td><td style="vertical-align:top"><p>25 mg (once a day)</p></td><td style="vertical-align:top"><p>50 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>100 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p><p><strong>&nbsp;</strong></p><p>(maximum daily dose of 200 mg)</p></td></tr><tr><td style="vertical-align:top"><p><strong>b) Adjunct therapy with inducers of lamotrigine glucuronidation in patients NOT taking inhibitors such as Valproate.</strong></p></td><td style="vertical-align:top"><p>50 mg (once a day)</p></td><td style="vertical-align:top"><p>100 mg</p><p><strong>&nbsp;</strong></p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>200 mg</p><p><strong>&nbsp;</strong></p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>300 mg in week 6, increasing to</p><p>400 mg/day if necessary, in week 7</p><p><strong>&nbsp;</strong></p><p>(two divided doses)</p></td></tr><tr><td style="vertical-align:top"><p><strong>This dosage regimen should be used with:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Phenytoin Carbamazepine Phenobarbitone Primidone</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Or with other inducers of lamotrigine glucuronidation (<em>see Interactions</em>)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>c) Monotherapy with</strong></p><p><strong><em>LAMICTAL</em></strong></p><p><strong>OR</strong></p><p><strong>Adjunctive therapy in patients taking other medications that do not significantly inhibit or induce lamotrigine</strong></p><p><strong>glucuronidation (<em>see Interactions</em>)</strong></p></td><td style="vertical-align:top"><p>25 mg (once a day)</p></td><td style="vertical-align:top"><p>50 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>100 mg</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>200 mg</p><p><strong>&nbsp;</strong></p><p>(Range 100 &ndash;</p><p>400 mg)</p><p><strong>&nbsp;</strong></p><p>(once a day or two divided doses)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>NOTE: In patients taking AEDs where the pharmacokinetic interaction with lamotrigine is currently not known, the dose escalation as recommended for <em>LAMICTAL </em>with concurrent valproate, should be used.</p></td></tr></tbody></table><p>**The target stabilisation dose will alter depending on clinical response.</p><p>&nbsp;</p><p><strong>a)&nbsp; </strong><strong>Adjunct therapy with inhibitors of lamotrigine glucuronidation e.g. Valproate </strong>In patients taking glucuronidation inhibiting concomitant drugs such as valproate, the initial <em>LAMICTAL </em>dose is 25 mg every alternate day for two weeks, followed by 25 mg once a day for two weeks. The dose should be increased to 50 mg once a day (or in two divided doses) in week 5. The usual target dose to achieve optimal response is</p><p>100 mg/day given once a day or in two divided doses. However, the dose can be increased to a maximum daily dose of 200 mg, depending on clinical response.</p><p>&nbsp;</p><p>b)&nbsp; Adjunct therapy with inducers of lamotrigine glucuronidation in patients NOT taking inhibitors such as Valproate. This dosage regimen should be used with phenytoin, carbamazepine, phenobarbitone, primidone and other drugs known to induce lamotrigine glucuronidation (<em>see Interactions</em>).<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_602eaaad-cf4e-48b0-9cc3-1f2097cf8e30 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>In those patients currently taking drugs that induce lamotrigine glucuronidation and NOT taking valproate, the initial <em>LAMICTAL </em>dose is 50 mg once a day for two weeks, followed by 100 mg/day given in two divided doses for two weeks. The dose should be increased to 200 mg/day given as two divided doses in week 5. The dose may be increased in week 6 to 300 mg/day however, the usual target dose to achieve optimal response is</p><p>400 mg/day given in two divided doses which may be given from week 7.</p><p>&nbsp;</p><p>c)&nbsp; Monotherapy with <em>LAMICTAL </em>OR adjunctive therapy in patients taking other medications that do not significantly induce or inhibit lamotrigine glucuronidation (<em>see Interactions</em>).<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0c8e55b3-1b62-4381-a025-612b32e3b9d0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>The initial <em>LAMICTAL </em>dose is 25 mg once a day for two weeks, followed by 50 mg once a day (or in two divided doses) for two weeks. The dose should be increased to 100 mg/day in week 5. The usual target dose to achieve optimal response is 200 mg/day given once a day or as two divided doses. However, a range of 100 to 400 mg was used in clinical trials.</p><p>Once the target daily maintenance stabilisation dose has been achieved, other psychotropic medications may be withdrawn as laid out in the dosage schedule below (see Table 4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 4: Maintenance stabilisation total daily dose in adults (18 years of age and over) with BIPOLAR DISORDER following withdrawal of concomitant psychotropic or anti-epileptic drugs<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8a25461b-08f8-4e5d-b7b3-ff112f26e489 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Week 1</strong></p></td><td style="vertical-align:top"><p><strong>Week 2</strong></p></td><td style="vertical-align:top"><p><strong>Week 3 onwards*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(a) Following withdrawal of inhibitors of lamotrigine glucuronidation e.g. </strong><strong>V</strong><strong>alproate</strong></p></td><td style="vertical-align:top"><p>Double the stabilisation dose, not exceeding 100 mg/week</p><p><strong>&nbsp;</strong></p><p>i.e. 100 mg/day target stabilisation dose will be increased in week 1 to 200 mg/day</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Maintain this dose (200 mg/day) (two divided doses)</p></td></tr><tr><td style="vertical-align:top"><p><strong>(b) Following withdrawal of inducers of lamotrigine glucuronidation depending on original dose.</strong></p><p><strong>&nbsp;</strong></p><p><strong>This dosage regimen should be used with:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Phenytoin Carbamazepine Phenobarbitone Primidone</strong></p><p><strong>&nbsp;</strong></p><p><strong>Or with other inducers of lamotrigine glucuronidation (<em>see Interactions</em>)</strong></p></td><td style="vertical-align:top"><p>400 mg</p></td><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>225 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>(c) Following withdrawal of other medications that do not significantly inhibit or induce lamotrigine glucuronidation (<em>see Interactions</em>)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Maintain target dose achieved in dose escalation (200 mg/day) (two divided doses)</p><p>(Range 100-400 mg)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>NOTE: In patients taking AEDs where the pharmacokinetic interaction with lamotrigine is currently not known, the treatment regimen recommended for <em>LAMICTAL </em>is to initially maintain the current dose and adjust the <em>LAMICTAL </em>treatment based on clinical response.</p></td></tr></tbody></table><p>* Dose may be increased to 400 mg/day as needed</p><p>&nbsp;</p><p>&nbsp;</p><p>(a)&nbsp;&nbsp; Following withdrawal of adjunct therapy with inhibitors of lamotrigine glucuronidation e.g. valproate<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_cc352e26-24c4-451f-abb2-c008a7fd313b \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>The dose of <em>LAMICTAL </em>should be increased to double the original target stabilisation dose and maintained at this, once valproate has been terminated.</p><p>&nbsp;</p><p>(b)&nbsp;&nbsp; Following withdrawal of adjunct therapy with inducers of lamotrigine glucuronidation depending on original maintenance dose. This regimen should be used with phenytoin, carbamazepine, phenobarbitone, primidone or other drugs known to induce <em>LAMICTAL </em>glucuronidation (<em>see Interactions</em>).<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_99d11692-9cbd-4799-b97b-289b9eb1607e \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>The dose of <em>LAMICTAL </em>should be gradually reduced over three weeks as the glucuronidation inducer is withdrawn.</p><p><strong>(c)&nbsp; </strong><strong>Following withdrawal of adjunct therapy with other medications that do not significantly inhibit or induce lamotrigine glucuronidation (<em>see Interactions</em>). </strong>The target dose achieved in the dose escalation programme should be maintained throughout withdrawal of the other medication.</p><p>&nbsp;</p><p><u>Adjustment of <em>LAMICTAL </em>daily dosing in patients with BIPOLAR DISORDER</u> <u>following addition of other medications</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9788cb2c-d4a8-4669-8c06-207a432e97d0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p>There is no clinical experience in adjusting the <em>LAMICTAL </em>daily dose following the addition of other medications. However, based on drug interaction studies, the following recommendations can be made (see Table 5, below):</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 5: Adjustment of <em>LAMICTAL </em>daily dosing in adults (18 years of age and over) with BIPOLAR DISORDER following the addition of other medications<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_bb57187a-f1e3-4ea8-a02f-b8d3b9f813cc \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Current <em>LAMICTAL </em>Stabilisation dose (mg/day)</strong></p></td><td style="vertical-align:top"><p><strong>Week 1</strong></p></td><td style="vertical-align:top"><p><strong>Week 2</strong></p></td><td style="vertical-align:top"><p><strong>Week 3 onwards</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>(a) Addition of inhibitors of lamotrigine glucuronidation e.g. Valproate, depending on original dose of <em>LAMICTAL</em></strong></p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (100 mg/day)</p></td></tr><tr><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (150 mg/day)</p></td></tr><tr><td style="vertical-align:top"><p>400 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (200 mg/day)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>(b) Addition of inducers of lamotrigine glucuronidation in patients NOT taking valproate and depending on original dose of <em>LAMICTAL</em>. This dosage regimen should be used with:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Phenytoin Carbamazepine Phenobarbitone Primidone</strong></p><p><strong>&nbsp;</strong></p><p><strong>Or with other inducers of lamotrigine glucuronidation (<em>see Interactions</em>)</strong></p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>400 mg</p></td></tr><tr><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>225 mg</p></td><td style="vertical-align:top"><p>300 mg</p></td></tr><tr><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>(c) Addition of other medications that do not significantly inhibit or induce lamotrigine glucuronidation (<em>see Interactions</em>)</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Maintain target dose achieved in dose escalation (200 mg/day) (range 100 - 400 mg)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>NOTE: In patients taking AEDs where the pharmacokinetic interaction with lamotrigine is currently not known, the treatment regimen as recommended for <em>LAMICTAL </em>with concurrent valproate, should be used.</p></td></tr></tbody></table><p>&nbsp;</p><p>GENERAL DOSING RECOMMENDATIONS FOR <em>LAMICTAL </em>IN SPECIAL PATIENT POPULATIONS<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_3c03c8c6-ac65-4072-aff4-18a50dec8b7c \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&middot;&nbsp; <strong>Women taking hormonal contraceptives</strong></p><p><strong>(a)&nbsp;&nbsp; </strong><strong>Starting <em>LAMICTAL </em>in patients already taking hormonal contraceptives:</strong></p><p><strong>&nbsp;</strong></p><p>Although an oral contraceptive has been shown to increase the clearance of lamotrigine (<em>see Warnings and Precautions and Interactions</em>), no adjustments to the recommended dose escalation guidelines for <em>LAMICTAL </em>should be necessary solely based on the use of hormonal contraceptives. Dose escalation should follow the recommended guidelines based on whether lamotrigine is added to valproate (an inhibitor of lamotrigine glucuronidation), or to an inducer of lamotrigine glucuronidation, or whether <em>LAMICTAL </em>is added in the absence of valproate or an inducer of lamotrigine glucuronidation (see Table 1 for epilepsy and Table 3 for bipolar disorder patients).</p><p>&nbsp;</p><p>&nbsp;</p><p>(b)&nbsp;&nbsp; Starting hormonal contraceptives in patients already taking maintenance doses of <em>LAMICTAL </em>and NOT taking inducers of lamotrigine glucuronidation:<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c558e498-f442-4611-a4cc-cd8a28930e60 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>The maintenance dose of <em>LAMICTAL </em>will in most cases need to be increased by as much as two-fold (<em>see Warnings and Precautions and Interactions</em>). It is recommended that from the time that the hormonal contraceptive is started, the lamotrigine dose is increased by 50 to 100 mg/day every week, according to the individual clinical response. Dose increases should not exceed this rate, unless the clinical response supports larger increases.</p><p>&nbsp;</p><p>(c)&nbsp; Stopping hormonal contraceptives in patients already taking maintenance doses of <em>LAMICTAL </em>and NOT taking inducers of lamotrigine glucuronidation:<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d1b0ebc3-ceac-4436-97ab-0bf3803b6df8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>The maintenance dose of <em>LAMICTAL </em>will in most cases need to be decreased by as much as 50% (<em>see Warnings and Precautions &amp; Interactions</em>). It is recommended to gradually decrease the daily dose of lamotrigine by 50 to 100 mg each week (at a rate not exceeding 25% of the total daily dose per week) over a period of 3 weeks, unless the clinical response indicates otherwise.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use with other oestrogen-containing products</strong></p><p>Other oestrogen-containing therapies, such as hormone replacement therapies (HRTs), may interfere with <em>LAMICTAL</em>. Therefore, close clinical monitoring on effectiveness of <em>LAMICTAL</em> with dose adjustment may be necessary <em>(see Warnings and Precautions).</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use with atazanavir/ritonavir<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_469ece3a-8cc3-480c-a601-fdc92ef80df5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Although atazanavir/ritonavir has been shown to reduce lamotrigine plasma concentrations (<em>see Interactions</em>), no adjustments to the recommended dose escalation guidelines for <em>LAMICTAL </em>should be necessary solely based on the use of atazanvir/ritonavir. Dose escalation should follow the recommended guidelines based on whether <em>LAMICTAL </em>is added to valproate (an inhibitor of lamotrigine glucuronidation), or to an inducer of lamotrigine glucuronidation, or whether <em>LAMICTAL </em>is added in the absence of valproate or an inducer of lamotrigine glucuronidation.</p><p>In patients already taking maintenance doses of <em>LAMICTAL </em>and not taking glucuronidation inducers, the <em>LAMICTAL </em>dose may need to be increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly (over 65 years of age)<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1d23f7c9-17d4-4e2c-87e2-c64faf97302e \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>No dosage adjustment from recommended schedule is required. The pharmacokinetics of <em>LAMICTAL </em>in this age group do not differ significantly from a non-elderly adult population.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic impairment<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6905d8cd-5aec-4082-a392-4f71c5c5422c \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Initial, escalation and maintenance doses should generally be reduced by approximately 50% in patients with moderate (Child-Pugh grade B) and 75% in severe (Child-Pugh grade C) hepatic impairment. Escalation and maintenance doses should be adjusted according to clinical response (<em>see Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_137ad2c0-dc2c-45a2-943f-2e77e950519a \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Caution should be exercised when administering <em>LAMICTAL </em>to patients with renal failure. For patients with end-stage renal failure, initial doses of <em>LAMICTAL </em>should be based on patients&#39; AED regimen; reduced maintenance doses may be effective for patients with significant renal functional impairment (<em>see Warnings and Precautions</em>). For more detailed pharmacokinetic information (<em>see Pharmacokinetics</em>).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LAMICTAL tablets and dispersible/chewable tablets are contraindicated in individuals with known hypersensitivity to, lamotrigine or any other ingredient of the preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.3&nbsp;&nbsp; Skin rash<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7eeb32cf-2cea-46f0-8fd1-8c9c8b76595d \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>There have been reports of adverse skin reactions, which have generally occurred within the first eight weeks after initiation of <em>LAMICTAL </em>treatment. The majority of rashes are mild and self-limiting, however serious rashes requiring hospitalisation and discontinuation of <em>LAMICTAL </em>have also been reported. These have included potentially life-threatening rashes such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (<em>see Adverse Reactions</em>).</p><p>&nbsp;</p><p>In adults enrolled in studies utilising the current <em>LAMICTAL </em>dosing recommendations, the incidence of serious skin rashes is approximately 1 in 500 in epilepsy patients.</p><p>Approximately half of these cases have been reported as SJS (1 in 1000).</p><p>&nbsp;</p><p>In clinical trials in patients with bipolar disorder, the incidence of serious rash is approximately 1 in 1000.</p><p>&nbsp;</p><p>The risk of serious skin rashes in children is higher than in adults.</p><p>&nbsp;</p><p>Available data from a number of studies suggest the incidence of rashes associated with hospitalisation in children is from 1 in 300 to 1 in 100.</p><p>&nbsp;</p><p>In children, the initial presentation of a rash can be mistaken for an infection. Physicians should consider the possibility of a drug reaction in children that develop symptoms of rash and fever during the first eight weeks of therapy.</p><p>&nbsp;</p><p>Additionally, the overall risk of rash appears to be strongly associated with:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high initial doses of <em>LAMICTAL </em>and exceeding the recommended dose escalation of <em>LAMICTAL </em>therapy (<em>see Dosage and Administration</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant use of valproate, (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p>Caution is also required when treating patients with a history of allergy or rash to other anti-epileptic drugs as the frequency of non-serious rash after treatment with <em>LAMICTAL </em>was approximately three times higher in these patients than in those without such history.</p><p>&nbsp;</p><p>HLA-B*1502 allele in individuals of Asian (primarily Han Chinese and Thai) origin has been shown to be associated with the risk of developing SJS/TEN when treated with lamotrigine. If these patients are known to be positive for HLA-B*1502, use of lamotrigine should be carefully considered.</p><p>&nbsp;</p><p>All patients (adults and children) who develop a rash should be promptly evaluated and <em>LAMICTAL </em>withdrawn immediately unless the rash is clearly not drug related. It is recommended that <em>LAMICTAL </em>not be restarted in patients who have discontinued due to rash associated with prior treatment with <em>LAMICTAL </em>unless the potential benefit clearly outweighs the risk.</p><p>&nbsp;</p><p>Rash has also been reported as part of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); also known as hypersensitivity syndrome. This condition is associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema, abnormalities of the blood, liver and kidney and aseptic meningitis (<em>see Adverse Reactions</em>). The syndrome shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation (DIC) and multi-organ failure. It is important to note that early manifestations of hypersensitivity (e.g. fever, lymphadenopathy) may be present even though rash is not evident. If such signs and symptoms are present, the patient should be evaluated immediately, and <em>LAMICTAL </em>discontinued if an alternative aetiology cannot be established.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Aseptic meningitis was reversible on withdrawal of the drug in most cases, but recurred in a number of cases on re-exposure to lamotrigine. Re-exposure resulted in a rapid return of symptoms that were frequently more severe. Lamotrigine should not be restarted in patients who have discontinued due to aseptic meningitis associated with prior treatment of lamotrigine.</p><p>&nbsp;</p><p><strong>Haemophagocytic lymphohistiocytosis (HLH)</strong></p><p>&nbsp;</p><p>HLH has occurred in patients taking <em>LAMICTAL</em> (<em>see Adverse Reactions</em>). HLH is a syndrome of pathological immune activation, which can be life threatening, characterised by clinical signs and symptoms such as fever, rash, neurological symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, high serum ferritin, hypertriglyceridaemia and abnormalities of liver function and coagulation. Symptoms occur generally within 4 weeks of treatment initiation.</p><p>&nbsp;</p><p>Immediately evaluate patients who develop these signs and symptoms and consider a diagnosis of HLH. <em>LAMICTAL</em> should be discontinued unless an alternative aetiology can be established.</p><p>&nbsp;</p><p>Suicide risk<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9aa55023-5c17-4c80-8190-95e9f0b1285f \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Symptoms of depression and/or bipolar disorder may occur in patients with epilepsy, and there is evidence that patients with epilepsy and bipolar disorder have an elevated risk for suicidality.</p><p>&nbsp;</p><p>Twenty-five to 50% of patients with bipolar disorder attempt suicide at least once, and may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking medications for bipolar disorder, including <em>LAMICTAL</em>.</p><p>&nbsp;</p><p>Suicidal ideation and behaviour have been reported in patients treated with AEDs in several indications, including epilepsy and bipolar disorder. A meta-analysis of randomised placebo-controlled trials of AEDs (including lamotrigine) has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known, and the available data do not exclude the possibility of an increased risk for lamotrigine.</p><p>&nbsp;</p><p>Therefore, patients should be monitored for signs of suicidal ideation and behaviours. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>&nbsp;</p><p>Clinical worsening in bipolar disorder<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_65a00d02-a227-4ef8-ba49-17ec9ceb8cfc \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Patients receiving <em>LAMICTAL </em>for bipolar disorder should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes. Certain patients, such as those with a history of suicidal behaviour or thoughts, young adults, and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, may be at a greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.</p><p>&nbsp;</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present.</p><p>&nbsp;</p><p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour,</p><p>&nbsp;</p><p>especially if these symptoms are severe, abrupt in onset, or were not part of the patient&rsquo;s presenting symptoms.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><u>Effects of oestrogen-containing products including hormonal contraceptives on <em>LAMICTAL </em>efficacy:</u></p><p>&nbsp;</p><p>An ethinylestradiol/levonorgestrel (30 micrograms/150 micrograms) combination has been demonstrated to increase the clearance of lamotrigine by approximately two-fold resulting in decreased lamotrigine levels (<em>see Interactions</em>). Following titration, higher maintenance doses of lamotrigine (by as much as two-fold) will be needed in most cases to attain a maximal therapeutic response. In women not already taking an inducer of lamotrigine glucuronidation and taking a hormonal contraceptive that includes one week of inactive medication (e.g. &quot;pill-free week&quot;), gradual transient increases in lamotrigine levels will occur during the week of inactive medication. These increases will be greater when lamotrigine dose increases are made in the days before or during the week of inactive medication. For dosing instructions see &quot;<em>General Dosing Recommendations for LAMICTAL in Special patient populations, Dosage and Administration</em>&quot;.</p><p>Clinicians should exercise appropriate clinical management of women starting or stopping hormonal contraceptives during <em>LAMICTAL </em>therapy and lamotrigine dosing adjustments will be needed in most cases.</p><p>&nbsp;</p><p>Other oral contraceptive and other oestrogen-containing therapies (such as HRT) have not been studied, though they may similarly affect lamotrigine pharmacokinetic parameters.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Effects of <em>LAMICTAL </em>on hormonal contraceptive efficacy:</u></p><p>&nbsp;</p><p>An interaction study in 16 healthy volunteers has shown that when lamotrigine and a hormonal contraceptive (ethinylestradiol/levonorgestrel combination) are administered in combination, there is a modest increase in levonorgestrel clearance and changes in serum FSH and LH (<em>see Interactions</em>). The impact of these changes on ovarian ovulatory activity is unknown. However, the possibility of these changes resulting in decreased contraceptive efficacy in some patients taking hormonal preparations with <em>LAMICTAL </em>cannot be excluded. Therefore, patients should be instructed to promptly report changes in their menstrual pattern, i.e. breakthrough bleeding.</p><p>&nbsp;</p><p>Effect of lamotrigine on organic cationic transporter 2 (OCT 2) substrates<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_66bbbf33-0617-4535-a3b6-47368270735b \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Lamotrigine is an inhibitor of renal tubular secretion via OCT 2 proteins (<em>see Interactions</em>). This may result in increased plasma levels of certain drugs that are substantially excreted via this route. Co-administration of <em>LAMICTAL </em>with OCT 2 substrates with a narrow therapeutic index e.g. dofetilide is not recommended.</p><p>&nbsp;</p><p>Dihydrofolate reductase<!--[if supportFields]><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_8b984f4f-2337-41aa-84b5-af3b48efb773
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Lamotrigine is a weak inhibitor of dihydrofolate reductase, hence there is a possibility of interference with folate metabolism during long-term therapy. However, during prolonged human dosing, <em>LAMICTAL </em>did not induce significant changes in the haemoglobin concentration, mean corpuscular volume, or serum or red blood cell folate concentrations up to 1 year or red blood cell folate concentrations for up to 5 years.</p><p>&nbsp;</p><p>Renal Failure<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fd55dfa0-a5ae-4b50-bba4-503dae903c08 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>In single dose studies in subjects with end-stage renal failure, plasma concentrations of lamotrigine were not significantly altered. However, accumulation of the glucuronide metabolite is to be expected; caution should therefore be exercised in treating patients with renal failure.</p><p>&nbsp;</p><p>Patients taking other preparations containing lamotrigine<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ef2a6e7a-3a5b-4d2d-9e64-9d3b3cc6b564 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><em>LAMICTAL </em>tablets and dispersible/chewable tablets should not be administered to patients currently being treated with any other preparation containing lamotrigine without consulting a doctor.</p><p>&nbsp;</p><p><strong>Brugada-type ECG</strong></p><p>&nbsp;</p><p>A very rare association with Brugada-type ECG has been observed, although a causal relationship has not been established. Therefore, careful consideration should be given before using <em>LAMICTAL</em> in patients with Brugada syndrome. (<em>see Pharmacodynamics</em>).</p><p>&nbsp;</p><p><strong>Cardiac rhythm and conduction abnormalities</strong></p><p><u>&nbsp;</u></p><p>In vitro testing showed that LAMICTAL exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations. Based on these in vitro findings, LAMICTAL could potentially slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with clinically important structural or functional heart disease. Therefore, any expected or observed benefit of LAMICTAL for those patients must be carefully weighed against the potential risks for serious or fatal cardiac events. Concomitant use of other sodium channel blockers may further increase the risk of proarrhythmia (<em>see Pharmacodynamics</em>).</p><p>&nbsp;</p><p>&nbsp;</p><p>EPILEPSY<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_ca3f1504-52c6-4eb8-933b-ad405bcd3090 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>As with other AEDs, abrupt withdrawal of <em>LAMICTAL </em>may provoke rebound seizures. Unless safety concerns (for example rash) require an abrupt withdrawal, the dose of <em>LAMICTAL </em>should be gradually decreased over a period of two weeks.</p><p>&nbsp;</p><p>There are reports in the literature that severe convulsive seizures including status epilepticus may lead to rhabdomyolysis, multi-organ dysfunction and disseminated intravascular coagulation, sometimes with fatal outcome. Similar cases have occurred in association with the use of <em>LAMICTAL</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p>BIPOLAR DISORDER<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_c750884f-602f-4a7d-99f5-ebbab59395dd \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong><u>Children and adolescents (less than 18 years of age)</u></strong></p><p><strong>&nbsp;</strong></p><p>Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with major depressive disorder and other psychiatric disorders.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Uridine 5&rsquo;-diphospho (UDP)-glucuronyl transferases (UGTs) have been identified as the enzymes responsible for metabolism of lamotrigine. Drugs that induce or inhibit glucuronidation may, therefore, affect the apparent clearance of lamotrigine. Strong or moderate inducers of the cytochrome P450 3A4 (CYP3A4) enzyme, which are also known to induce UGTs, may also enhance the metabolism of lamotrigine. There is no evidence that lamotrigine causes clinically significant induction or inhibition of cytochrome P450 enzymes. Lamotrigine may induce its own metabolism, but the effect is modest and unlikely to have significant clinical consequences.</p><p>&nbsp;</p><p>&nbsp;</p><p>Those drugs that have been demonstrated to have a clinically relevant impact on lamotrigine concentration are outlined in Table 6. Specific dosing guidance for these drugs is provided in Dosage and Administration. In addition, this table lists those drugs which have been shown to have little or no effect on the concentration of lamotrigine.&nbsp; Coadministration of such drugs would generally not be expected to result in any clinical impact.&nbsp; However, consideration should be given to patients whose epilepsy is especially sensitive to fluctuations in concentrations of lamotrig</p><p>&nbsp;</p><p><strong>Table 6: Effects of&nbsp; drugs on the concentration of lamotrigine </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td style="vertical-align:top"><p><strong>Drugs that increase the concentration of lamotrigine</strong></p></td><td style="vertical-align:top"><p><strong>Drugs that </strong><strong>decrease the concentration of lamotrigine</strong></p></td><td style="vertical-align:top"><p><strong>Drugs that have little or no effect on the concentration of lamotrigine</strong></p></td></tr><tr><td style="vertical-align:top"><p>Valproate</p></td><td style="vertical-align:top"><p>Atazanavir/ritonavir</p></td><td style="vertical-align:top"><p>Aripiprazole</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Bupropion</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ethinylestradiol / levonorgestrel combination</p></td><td style="vertical-align:top"><p>Felbamate</p><p>Gabapentin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>Lacosamide &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phenobarbitone</p></td><td style="vertical-align:top"><p>Levetiracetam</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Lithium</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Primidone</p></td><td style="vertical-align:top"><p>Olanzapine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rifampicin</p></td><td style="vertical-align:top"><p>Oxcarbazepine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paracetamol</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Perampanel&nbsp;</p><p>Pregabalin &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Topiramate</p><p>Zonisamide</p></td></tr></tbody></table><p>&nbsp;</p><p>* For dosing guidance, <em>see Dosage and Administration &mdash; General Dosing Recommendations for LAMICTAL in Special patient populations</em>, plus for women taking hormonal contraceptives also see Warnings and Precautions &ndash;</p><p><em>Effects of oestrogen-containing products including hormonal contraceptives on LAMICTAL efficacy and Effects of LAMICTAL on hormonal contraceptive efficacy</em>.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Interactions involving AEDs (<em>see Dosage and Administration</em>)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Valproate, which inhibits the glucuronidation of lamotrigine, reduces the metabolism of lamotrigine and increases the mean half-life of lamotrigine nearly two-fold.</p><p>&nbsp;</p><p>Certain AEDs (such as phenytoin, carbamazepine, phenobarbitone and primidone) which induce cytochrome P450 enzymes also induce UGTs and, therefore, enhance the metabolism of lamotrigine.</p><p>&nbsp;</p><p>There have been reports of central nervous system events including dizziness, ataxia, diplopia, blurred vision and nausea in patients taking carbamazepine following the introduction of <em>LAMICTAL</em>. These events usually resolve when the dose of carbamazepine is reduced. A similar effect was seen during a study of lamotrigine and oxcarbazepine in healthy adult volunteers, but dose reduction was not investigated.</p><p>&nbsp;</p><p>&nbsp;</p><p>In a study in healthy adult volunteers using doses of 200 mg lamotrigine and 1200 mg oxcarbazepine, oxcarbazepine did not alter the metabolism of lamotrigine and lamotrigine did not alter the metabolism of oxcarbazepine.</p><p>&nbsp;</p><p>In a study of healthy volunteers, co-administration of felbamate (1200 mg twice daily) with <em>LAMICTAL </em>(100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.</p><p>&nbsp;</p><p>Based on a retrospective analysis of plasma levels in patients who received <em>LAMICTAL </em>both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine.</p><p>&nbsp;</p><p>Potential drug interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents during placebo-controlled clinical trials. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.</p><p>&nbsp;</p><p>Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg 3 times daily) administration. There are no pharmacokinetic interactions between lamotrigine and pregabalin.</p><p>&nbsp;</p><p>Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of <em>LAMICTAL </em>resulted in a 15% increase in topiramate concentrations.</p><p>&nbsp;</p><p>In a study of patients with epilepsy, co-administration of zonisamide (200 to 400 mg/day) with <em>LAMICTAL </em>(150 to 500 mg/day) for 35 days had no significant effect on the pharmacokinetics of lamotrigine.</p><p>&nbsp;</p><p>Plasma concentrations of lamotrigine were not affected by concomitant lacosamide (200, 400, or 600 mg/day) in placebo-controlled clinical trials in patients with partial-onset seizures.</p><p>&nbsp;</p><p>&nbsp;</p><p>In a pooled analysis of data from three placebo-controlled clinical trials investigating adjunctive perampanel in patients with partial-onset and primary generalised tonic-clonic seizures, the highest perampanel dose evaluated (12 mg/day) increased lamotrigine clearance by less than 10%.</p><p>&nbsp;</p><p>Although changes in the plasma concentrations of other anti-epileptic drugs have been reported, controlled studies have shown no evidence that lamotrigine affects the plasma concentrations of concomitant anti-epileptic drugs. Evidence from <em>in vitro </em>studies indicates that lamotrigine does not displace other anti-epileptic drugs from protein binding sites.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Interactions involving other psychoactive agents (<em>see Dosage and Administration</em>)</strong></p><p><strong>&nbsp;</strong></p><p>The pharmacokinetics of lithium after 2 g of anhydrous lithium gluconate given twice daily for six days to 20 healthy subjects were not altered by co-administration of</p><p>100 mg/day <em>LAMICTAL</em>.</p><p>&nbsp;</p><p>Multiple oral doses of bupropion had no statistically significant effects on the single dose pharmacokinetics of <em>LAMICTAL </em>in 12 subjects and had only a slight increase in the AUC of lamotrigine glucuronide.</p><p>&nbsp;</p><p>In a study in healthy adult volunteers, 15 mg olanzapine reduced the AUC and Cmax of lamotrigine by an average of 24% and 20%, respectively. Lamotrigine at 200 mg did not affect the pharmacokinetics of olanzapine.</p><p>&nbsp;</p><p>Multiple oral doses of <em>LAMICTAL </em>400 mg daily had no clinically significant effect on the single dose pharmacokinetics of 2 mg risperidone in 14 healthy adult volunteers.</p><p>Following the co-administration of risperidone 2 mg with lamotrigine, 12 out of the</p><p>14 volunteers reported somnolence compared to 1 out of 20 when risperidone was given alone, and none when <em>LAMICTAL </em>was administered alone.</p><p>&nbsp;</p><p>In a study of 18 adult patients with bipolar I disorder, receiving an established regimen of lamotrigine (&gt;/=100 mg/day), doses of aripiprazole were increased from 10 mg/day to a target of 30 mg/day over a 7-day period and continued once daily for a further 7 days. An average reduction of approximately 10% in Cmax and AUC of lamotrigine was observed.</p><p>&nbsp;</p><p><em>In vitro </em>inhibition experiments indicated that the formation of lamotrigine&#39;s primary metabolite, the 2-N-glucuronide, was minimally affected by co-incubation with amitriptyline, bupropion, clonazepam, fluoxetine, haloperidol, or lorazepam. Bufuralol metabolism data from human liver microsome suggested that lamotrigine does not reduce the clearance of drugs eliminated predominantly by CYP2D6. Results of <em>in vitro </em>experiments also suggest that clearance of lamotrigine is unlikely to be affected by clozapine, phenelzine, risperidone, sertraline or trazodone.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interactions involving hormonal contraceptives<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f9fcce03-4d12-45ad-974c-eee3507c9367 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>Effect of hormonal contraceptives on lamotrigine pharmacokinetics</strong></p><p><strong>&nbsp;</strong></p><p>In a study of 16 female volunteers, 30 micrograms ethinylestradiol/150 micrograms levonorgestrel in a combined oral contraceptive pill caused an approximately two-fold increase in lamotrigine oral clearance, resulting in an average 52% and 39% reduction in lamotrigine AUC and Cmax, respectively. Serum lamotrigine concentrations gradually increased during the course of the week of inactive medication (e.g. &quot;pill-free&quot; week), with pre-dose concentrations at the end of the week of inactive medication being, on average, approximately two-fold higher than during co-therapy - <em>see Dosage and Administration - General Dosing Recommendations for LAMICTAL in Special patient populations </em>(for dosing instructions for women taking oestrogen-containing products including hormonal contraceptives) and <em>Warnings and Precautions &ndash; &nbsp;Effects of oestrogen-containing products including hormonal contraceptives on LAMICTAL efficacy and Effects of LAMICTAL on hormonal contraceptive efficacy.</em></p><p>Effect of lamotrigine on hormonal contraceptive pharmacokinetics<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_30ae411e-bd87-440a-992b-e02038828bc9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>In a study of 16 female volunteers, a steady state dose of 300 mg lamotrigine had no effect on the pharmacokinetics of the ethinylestradiol component of a combined oral contraceptive pill. A modest increase in oral clearance of the levonorgestrel component was observed, resulting in an average 19% and 12% reduction in levonorgestrel AUC and Cmax, respectively. Measurement of serum FSH, LH and estradiol during the study indicated some loss of suppression of ovarian hormonal activity in some women, although measurement of serum progesterone indicated that there was no hormonal evidence of ovulation in any of the 16 subjects. The impact of the modest increase in levonorgestrel clearance, and the changes in serum FSH and LH, on ovarian ovulatory activity is unknown (<em>see Warnings and Precautions</em>). The effects of doses of lamotrigine other than 300 mg/day have not been studied and studies with other female hormonal preparations (including progesterone/progesterone-containing HRT) have not been conducted.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interactions involving other medications<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_641c00af-3088-461c-94a5-29775543e30b \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>In a study in 10 male volunteers, rifampicin increased lamotrigine clearance and decreased lamotrigine half-life due to induction of the hepatic enzymes responsible for glucuronidation. In patients receiving concomitant therapy with rifampicin, the treatment regimen recommended for lamotrigine and concurrent glucuronidation inducers should be used (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p>In a study in healthy volunteers, lopinavir/ritonavir approximately halved the plasma concentrations of lamotrigine, probably by induction of glucuronidation. In patients receiving concomitant therapy with lopinavir/ritonavir, the treatment regimen recommended for lamotrigine and concurrent glucuronidation inducers should be used (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p>In a study in healthy adult volunteers, atazanavir/ritonavir (300 mg/100 mg) reduced the plasma AUC and Cmax of lamotrigine (single 100 mg dose) by an average of 32% and</p><p>&nbsp;</p><p>&nbsp;</p><p>6%, respectively (<em>see Dosage and Administration - General Dosing Recommendations for LAMICTAL in Special Patient Populations</em>).</p><p>&nbsp;</p><p>In a study in healthy adult volunteers, paracetamol 1g (four times daily) reduced the plasma AUC and C<sub>min</sub> of lamotrigine by an average of 20% and 25%, respectively.</p><p>Data from <em>in vitro </em>assessment of the effect of lamotrigine at OCT 2 demonstrate that lamotrigine, but not the N(2)-glucuronide metabolite, is an inhibitor of OCT 2 at potentially clinically relevant concentrations. These data demonstrate that lamotrigine is an inhibitor of OCT 2, with an IC50 value of 53.8 &micro;M (<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interactions involving laboratory tests<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7f5de926-b59f-4a97-8da6-77f90986a88a \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><em>LAMICTAL </em>has been reported to interfere with the assay used in some rapid urine drug screens, which can result in false positive readings, particularly for phencyclidine (PCP). A more specific alternative chemical method should be used to confirm a positive result.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>Administration of lamotrigine did not impair fertility in animal reproductive studies. There is no experience of the effect of <em>LAMICTAL </em>on human fertility</p><p>Pregnancy<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7a53577c-b73d-4840-8030-b436f71e76ab \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;Several meta-analyses have not reported an increased risk of major congenital malformations following lamotrigine exposure in pregnancy compared with healthy and disease-matched controls. No patterns of specific malformation types were observed.</p><p>The same meta-analyses evaluated the risk of additional maternal and infant outcomes including fetal death, stillbirth, preterm birth, small for gestational age, and neurodevelopmental delay. Although there are no data suggesting an increased risk of these outcomes with lamotrigine monotherapy exposure, differences in outcome definition, ascertainment methods, and comparator groups limit the conclusions that can be drawn.<!--[if supportFields]><span
lang=EN-US style='mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_35a68540-2d43-4fc4-b1a7-e9939f90a664 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA;font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>In animal studies lamotrigine was not teratogenic in animal reproductive studies involving mice, rats, and rabbits using (oral doses of up to 125, 25, and 30 mg/kg, respectively), during period of organogenesis, reduced fetal body weight and increased incidences of fetal skeletal variations were seen in mice and rats at doses that were also maternally toxic. The no-effect doses for embryofetal developmental toxicity in mice, rats, and rabbits (75, 6.25, and 30 mg/kg, respectively) are similar to (mice and rabbits) or less than (rats) the human dose of 400 mg/day on a body surface area (mg/m2) basis.</p><p>When pregnant rats were administered lamotrigine (oral doses of 0, 5, 10, or 20 mg/kg) during</p><p>the latter part of gestation and throughout lactation, increased offspring mortality (including</p><p>stillbirths) was seen at all doses. The lowest effect dose for pre- and post-natal developmental</p><p>toxicity in rats is less than the human dose of 400 mg/day on a mg/m2 basis. Maternal toxicity</p><p>was observed at the 2 highest doses tested.</p><p>When administered to pregnant rats, lamotrigine decreased fetal folate concentrations at doses</p><p>greater than or equal to 5 mg/kg/day, which is less than the human dose of 400 mg/day on a</p><p>mg/m2 basis.</p><p>&nbsp;</p><p>In human data, data from several international pregnancy registries have not shown an increased</p><p>risk for malformations overall. The International Lamotrigine Pregnancy Registry reported major congenital malformations in 2.2% (95% CI: 1.6%, 3.1%) of 1,558 infants exposed to lamotrigine monotherapy in the first trimester of pregnancy. The NAAED Pregnancy Registry reported major congenital malformations among 2.0% of 1,562 infants exposed to lamotrigine monotherapy in the first trimester. EURAP, a large international pregnancy registry focused outside of North America, reported major birth defects in 2.9% (95% CI: 2.3%, 3.7%) of 2,514 exposures to lamotrigine monotherapy in the first trimester. The frequency of major congenital malformations was similar to estimates from the general population.</p><p><em><u>&nbsp;</u></em></p><p>The NAAED Pregnancy Registry observed an increased risk of isolated oral clefts: among 2,200</p><p>infants exposed to lamotrigine early in pregnancy, the risk of oral clefts was 3.2 per 1,000 (95%</p><p>CI: 1.4, 6.3), a 3-fold increased risk versus unexposed healthy controls. This finding has not been</p><p>observed in other large international pregnancy registries. Furthermore, a case-control study</p><p>based on 21 congenital anomaly registries covering over 10 million births in Europe reported an</p><p>adjusted odds ratio for isolated oral clefts with lamotrigine exposure of 1.45 (95% CI: 0.8, 2.63).</p><p><em><u>&nbsp;</u></em></p><p>Physiological changes during pregnancy may affect lamotrigine levels and/or therapeutic effect. There have been reports of decreased lamotrigine plasma levels during pregnancy with a potential risk of loss of seizure control. After birth lamotrigine levels may increase rapidly with a risk of dose-related adverse events. Therefore, lamotrigine serum concentrations should be monitored before, during and after pregnancy, as well as shortly after birth. If necessary, the dose should be adapted to maintain the lamotrigine serum concentration at the same level as before pregnancy, or adapted according to clinical response. In addition, dose-related undesirable effects should be monitored after birth.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>Postmarketing data from several prospective pregnancy registries have documented outcomes in over 8,700 women exposed to <em>LAMICTAL </em>monotherapy during the first trimester of pregnancy. Overall, these data do not suggest a substantial increase in the risk for major congenital malformations. Although data from a limited number of registries have reported an increase in the risk of isolated oral cleft malformations, a completed case control study did not demonstrate an increased risk of oral clefts compared to other major congenital malformations following exposure to lamotrigine <em>(see Pre-clinical Safety Data).</em></p><p>The data on use of <em>LAMICTAL </em>in polytherapy combinations are insufficient to assess whether the risk of malformation associated with other agents is affected by concomitant <em>LAMICTAL </em>use.</p><p>&nbsp;</p><p>As with other medicines, <em>LAMICTAL </em>should only be used during pregnancy if the expected benefits outweigh the potential risks.</p><p>&nbsp;</p><p>Physiological changes during pregnancy may affect lamotrigine levels and/or therapeutic effect. There have been reports of decreased lamotrigine levels during pregnancy.</p><p>Appropriate clinical management of pregnant women during <em>LAMICTAL </em>therapy should be ensured.</p><p>&nbsp;</p><p>Lactation<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8c98c7d0-189a-4223-9385-effb6459a7e0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Lamotrigine has been reported to pass into breast milk in highly variable concentrations, resulting in total lamotrigine levels in infants of up to approximately 50% of the mother&rsquo;s. Therefore, in some breast-fed infants, serum concentrations of lamotrigine may reach levels at which pharmacological effects occur.</p><p>&nbsp;</p><p>The potential benefits of breastfeeding should be weighed against the potential risk of adverse effects occurring in the infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>4.3&nbsp;&nbsp; Effects on Ability to Drive and Use Machines<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4863a5b9-c698-4df4-a8d6-07615f6be1b0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Two volunteer studies have demonstrated that the effect of <em>LAMICTAL </em>on fine visual motor co-ordination, eye movements, body sway and subjective sedative effects did not differ from placebo. In clinical trials with <em>LAMICTAL, </em>adverse events of a neurological character such as dizziness and diplopia have been reported. Therefore, patients should see how <em>LAMICTAL </em>therapy affects them before driving or operating machinery.</p><p>&nbsp;</p><p>Epilepsy<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c045e637-323f-4b3a-a58f-18ed4cd28d07 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>As there is individual variation in response to all anti-epileptic drug therapy, patients should consult their physician on the specific issues of driving and epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions identified from epilepsy or bipolar disorder clinical trial data have been divided into indication specific sections. Additional adverse reactions identified through post-marketing surveillance for both indications are included in the</p><p>post-marketing section. All three sections should be consulted when considering the overall safety profile of <em>LAMICTAL</em>.</p><p>&nbsp;</p><p>The following convention has been utilised for the classification of undesirable effects: Very common (&sup3; 1/10); common (&sup3; 1/100 to &lt; 1/10); uncommon (&sup3; 1/1000 to &lt; 1/100); rare (&sup3; 1/10,000 to &lt; 1/1000); very rare (&lt; 1/10,000).</p><p>&nbsp;</p><p><strong>Clinical trial data</strong></p><p>EPILEPSY<!--[if supportFields]><span style='mso-element:
field-begin'></span> DOCVARIABLE VAULT_ND_eee0cf3d-a47d-4a0a-9c41-2e77a6809acc
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>The following adverse reactions were identified during epilepsy clinical trials and should be considered alongside those seen in the bipolar disorder clinical trials and</p><p>post-marketing sections for an overall safety profile of <em>LAMICTAL</em>.</p><p><u>Skin and subcutaneous tissue disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_dfeb6fbe-2aae-45aa-919a-d1bcbd65b5ca \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash<!--[if supportFields]><span
style='font-weight:normal;mso-bidi-font-weight:bold'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_5703f883-9837-4fc1-b1b1-efffe3b97869
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal;mso-bidi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p><p><strong>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Erythema multiforme, Stevens-Johnson syndrome</p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; </strong>Toxic epidermal necrolysis</p><p>&nbsp;</p><p>In double-blind, add-on clinical trials in adults, skin rashes occurred in up to 10% of patients taking <em>LAMICTAL </em>and in 5% of patients taking placebo. The skin rashes led to the withdrawal of <em>LAMICTAL </em>treatment in 2% of patients. The rash, usually maculopapular in appearance, generally appears within eight weeks of starting treatment and resolves on withdrawal of <em>LAMICTAL </em>(<em>see Warnings and Precautions</em>).</p><p>&nbsp;</p><p>Rarely, serious potentially life-threatening skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell&rsquo;s syndrome) have been reported. Although the majority recover on drug withdrawal, some patients experience irreversible scarring and there have been rare cases of associated death (<em>see Warnings and Precautions</em>).</p><p>The overall risk of rash appears to be strongly associated with:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high initial doses of <em>LAMICTAL </em>and exceeding the recommended dose escalation of <em>LAMICTAL </em>therapy (<em>see Dosage and Administration</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant use of valproate (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p>Rash has also been reported as part of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); also known as &nbsp;hypersensitivity syndrome. This condition is associated with a variable pattern of systemic symptoms (<em>see Warnings and Precautions and Immune system disorders**</em>).</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_faf56180-a29d-4db8-b7b6-da256383c589 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Haematological abnormalities (including, neutropenia,</p><p>leucopenia, anaemia, thrombocytopenia, pancytopenia, aplastic anaemia, agranulocytosis), lymphadenopathy</p><p><strong>Unknow: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong>Pseudolymphoma</p><p>&nbsp;</p><p>Haematological abnormalities and lymphadenopathy may or may not be associated with DRESS/Hypersensitivity Syndrome (<em>see Warnings and Precautions and Immune system disorders**</em>).</p><p>&nbsp;</p><p><u>Immune system disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a3429e0d-bede-47e4-a19d-fcb9b54ab049 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>DRESS/<strong> </strong>Hypersensitivity syndrome** including such symptoms as, fever, lymphadenopathy, facial oedema, abnormalities of the blood, liver and kidney.</p><p>**Rash has also been reported as part of this syndrome which shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation (DIC) and multi-organ failure. It is important to note that early manifestations of hypersensitivity (e.g. fever, lymphadenopathy) may be present even though rash is not evident. If such signs and symptoms are present, the patient should be evaluated immediately and <em>LAMICTAL </em>discontinued if an alternative aetiology cannot be established.</p><p>&nbsp;</p><p><u>Psychiatric disorders</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_67f1b688-a258-4b8b-aca7-b9d4a168efef \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Aggression, irritability</p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Tics (motor and/or phonic tics), hallucinations, confusion</p><p>&nbsp;</p><p><u>Nervous system disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5466ca8c-59e1-46d0-b9a1-cfc0c68681e8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Headache</p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Somnolence, insomnia, dizziness, tremor</p><p><strong>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Ataxia</p><p><strong>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Nystagmus</p><p>&nbsp;</p><p><u>Eye disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2b4a1965-c140-4132-9cd9-366f96f9ba26 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Diplopia, blurred vision</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1e74c7f0-a137-453c-a5bc-08e740dc513d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Nausea, vomiting, diarrhoea</p><p>&nbsp;</p><p><u>Hepatobiliary disorders</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c9297cc1-3929-46dd-be50-e6b42ca6fa0a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Increased liver function tests, hepatic dysfunction, hepatic failure</p><p>&nbsp;</p><p>Hepatic dysfunction usually occurs in association with hypersensitivity reactions, but isolated cases have been reported without overt signs of hypersensitivity.</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_98114477-87bd-4511-aade-0bf385fcb6b2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Lupus-like reactions</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_93dc6828-1e5a-4f06-8bf3-29a0345f8a6a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Tiredness</p><p>&nbsp;</p><p>BIPOLAR DISORDER<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_eedffabd-1536-4872-827a-fecc286722c2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>The following adverse reactions were identified during bipolar disorder clinical trials and should be considered alongside those seen in the epilepsy clinical trials and</p><p>post-marketing sections for an overall safety profile of <em>LAMICTAL</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4148ac63-4253-476e-977b-34f00f7831d0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Skin rash</p><p><strong>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Erythema multiforme<strong>, </strong>Stevens-Johnson syndrome</p><p>&nbsp;</p><p>When all bipolar disorder studies (controlled and uncontrolled) conducted with <em>LAMICTAL </em>are considered, skin rashes occurred in 12% of patients on <em>LAMICTAL</em>. Whereas, in controlled clinical trials with bipolar disorder patients, skin rashes occurred in 8% of patients taking <em>LAMICTAL </em>and in 6% of patients taking placebo.</p><p>&nbsp;</p><p><u>Nervous system disorders</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_218fcd9b-8c43-45a8-bc71-118c6bd49ddc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Headache</p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Agitation, somnolence, dizziness</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7cade4d7-6d6f-45b0-bb87-0e3a4027a273 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Arthralgia</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4416d865-e405-4c0f-bd5a-9cbd09576664 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Pain, back pain</p><p>&nbsp;</p><p><strong>Post-marketing data:</strong></p><p>This section includes adverse reactions identified through post-marketing surveillance for both indications. These adverse reactions should be considered alongside those seen in the epilepsy and bipolar disorder clinical trials sections for an overall safety profile of <em>LAMICTAL</em>.</p><p><strong><u>Blood and lymphatic system disorders </u></strong></p><p><strong>Very rare:&nbsp; </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemophagocytic lymphohistiocytosis <em>(see</em> <em>Warnings and</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Precautions</em>), pseudolymphoma</p><p><strong><u>Immune system disorders</u></strong></p><p><strong>Very rare:&nbsp; </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia</p><p><strong><u>Psychiatric disorders</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Nightmares</p><p><u>Nervous system disorders</u><!--[if supportFields]><u style='text-underline:thick'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9d1c272c-594f-4913-ba81-3f5e0cb2ba00 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Somnolence, ataxia, headache, dizziness</p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Nystagmus, tremor, insomnia</p><p><strong>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Aseptic meningitis (<em>see Warnings and Precautions</em>)</p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Agitation, unsteadiness, movement disorders, worsening of Parkinson&#39;s disease, extrapyramidal effects, choreoathetosis</p><p>&nbsp;</p><p>&nbsp;</p><p>There have been reports that <em>LAMICTAL </em>may worsen parkinsonian symptoms in patients with pre-existing Parkinson&rsquo;s disease, and isolated reports of extrapyramidal effects and choreoathetosis in patients without this underlying condition.</p><p>&nbsp;</p><p><u>Eye disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8dd9f451-5936-400c-99ec-d3451a2a7aa2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Diplopia, blurred vision</p><p><strong>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Conjunctivitis</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2524f246-bfd0-4368-85af-0bdb83fd1095 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Nausea, vomiting</p><p><strong>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Diarrhoea</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u><!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_22de51e5-97a3-4a68-a26b-543e75bf9571 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia<!--[if supportFields]><span
style='mso-bidi-font-weight:normal'><span style='mso-element:field-begin'></span></span><span
style='font-weight:normal;mso-bidi-font-weight:bold'> DOCVARIABLE
vault_nd_dc5ddd3f-77f3-4346-9f13-fbbabe97fc92 \* MERGEFORMAT </span><span
style='mso-bidi-font-weight:normal'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p><u>&nbsp;</u></p><p><u>Renal and Urinary disorders</u><!--[if supportFields]><u><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_34d57022-838c-4335-9362-174330f8fd6f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-element:field-end'></span></u><![endif]--></p><p><u>&nbsp;</u></p><p><strong>Very Rare:</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tubulointerstitial nephritis*</p><p><u>&nbsp;</u></p><p>* may occur in association with uveitis</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Epilepsy only</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9f05a1a0-23c6-49c3-a714-41c37aadfbac \* MERGEFORMAT <span
style='mso-element:field-separator'></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u
style='text-underline:thick'><span style='mso-element:field-end'></span></u><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong><u>Nervous system disorders</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Increase in seizure frequency</p><p>&nbsp;</p><p>To report any side effect(s):<!--[if supportFields]><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_e6d15727-cbaf-45e8-ab9c-b7cc4c86bd04
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Kingdom of Saudi Arabia<!--[if supportFields]><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_6cfc754c-a15f-4a59-9e9d-76fc2a0fca48
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong><em>&nbsp;</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute ingestion of doses in excess of 10 to 20 times the maximum therapeutic dose, have been reported, including fatal cases. Overdose has resulted in symptoms including nystagmus, ataxia, impaired consciousness, grand mal convulsion and coma. QRS broadening (intraventricular conduction delay) has also been observed in overdose patients.</p><p>&nbsp;</p><p>&nbsp;</p><p>In the event of overdosage, the patient should be admitted to hospital and given appropriate supportive therapy <strong>&nbsp;</strong>Therapy aimed at decreasing absorption (activated charcoal) should be performed if indicated. Further management should be as clinically indicated, taking into account potential effects on cardiac conduction (see section 4.4). Use of intravenous lipid therapy may be considered for treatment of cardiotoxicity that responds insufficiently to sodium bicarbonate. There is no experience with haemodialysis as treatment of overdose. In six volunteers with kidney failure, 20% of the lamotrigine was removed from the body during a 4-hour haemodialysis session (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>ATC Code: </em></strong>N 03 AX 09</p><p>&nbsp;</p><p><strong><em>Mechanism of Action</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The results of pharmacological studies suggest that lamotrigine is a use-dependent blocker of voltage-gated sodium channels. It produces a use- and voltage-dependent block of sustained repetitive firing in cultured neurones and inhibits pathological release of glutamate (the amino acid which plays a key role in the generation of epileptic seizures), as well as inhibiting glutamate-evoked bursts of action potentials.</p><p>&nbsp;</p><p><strong><em>Pharmacodynamic Effects</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>In vitro</em> studies show that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations. It inhibits human cardiac sodium channels with rapid onset and offset kinetics and strong voltage dependence, consistent with other Class IB antiarrhythmic agents. At therapeutic doses, lamotrigine did not slow ventricular conduction (widen QRS) in healthy individuals in a thorough QT study; however, in patients with clinically important structural or functional heart disease lamotrigine could potentially slow ventricular conduction (widen QRS) and induce proarrhythmia.</p><p>In tests designed to evaluate the central nervous system effects of drugs, the results obtained using doses of 240 mg lamotrigine administered to healthy volunteers did not differ from placebo, whereas both 1000 mg phenytoin and 10 mg diazepam each significantly impaired fine visual motor co-ordination and eye movements, increased body sway and produced subjective sedative effects.</p><p>&nbsp;</p><p>In another study, single oral doses of 600 mg carbamazepine significantly impaired fine visual motor co-ordination and eye movements, while increasing both body sway and heart rate, whereas results with lamotrigine at doses of 150 mg and 300 mg did not differ from placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Lamotrigine is rapidly and completely absorbed from the gut with no significant first pass metabolism. Peak plasma concentrations occur approximately 2.5 hours after oral drug administration. Time to maximum concentration is slightly delayed after food but the extent of absorption is unaffected. The pharmacokinetics are linear up to 450 mg, the highest single dose tested. There is considerable inter-individual variation in steady state maximum concentrations but within an individual concentration rarely vary.</p><p>&nbsp;</p><p><strong><em>Distribution</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Binding to plasma proteins is about 55%; it is very unlikely that displacement from plasma proteins would result in toxicity.</p><p>&nbsp;</p><p>&nbsp;</p><p>The volume of distribution is 0.92 to 1.22 L/kg.</p><p>&nbsp;</p><p><strong><em>Metabolism</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>UDP-glucuronyl transferases have been identified as the enzymes responsible for metabolism of lamotrigine.</p><p>&nbsp;</p><p>Lamotrigine induces its own metabolism to a modest extent depending on dose. However, there is no evidence that lamotrigine affects the pharmacokinetics of other AEDs and data suggest that interactions between lamotrigine and drugs metabolised by cytochrome P450 enzymes are unlikely to occur.</p><p>&nbsp;</p><p><strong><em>Elimination</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The mean steady state clearance in healthy adults is 39  14 mL/min. Clearance of lamotrigine is primarily metabolic with subsequent elimination of glucuronide-conjugated material in urine. Less than 10% is excreted unchanged in the urine. Only about 2% of drug-related material is excreted in faeces. Clearance and half-life are independent of dose. The mean elimination half-life in healthy adults is 24 to 35 hours. In a study of subjects with Gilbert&#39;s Syndrome, mean apparent clearance was reduced by 32% compared with normal controls but the values are within the range for the general population.</p><p>The half-life of lamotrigine is greatly affected by concomitant medication. Mean half-life is reduced to approximately 14 hours when given with glucuronidation-inducing drugs such as carbamazepine and phenytoin and is increased to a mean of approximately</p><p>70 hours when co-administered with valproate alone (<em>see Dosage and Administration and Interactions</em>).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Special Patient Populations<!--[if supportFields]><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_c1ab12d9-8622-4256-91ba-e9167d861b08
\* MERGEFORMAT<span style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children</strong></p><p>Clearance adjusted for bodyweight is higher in children than in adults with the highest values in children under five years. The half-life of lamotrigine is generally shorter in children than in adults with a mean value of approximately 7 hours when given with enzyme-inducing drugs such as carbamazepine and phenytoin and increasing to mean values of 45 to 50 hours when co-administered with valproate alone. (<em>See Dosage and Administration</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly<!--[if supportFields]><span style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_4df44106-41d6-4425-aadc-5ecdcb34c106 \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Results of a population pharmacokinetic analysis including both young and elderly patients with epilepsy, enrolled in the same trials, indicated that the clearance of lamotrigine did not change to a clinically relevant extent. After single doses apparent clearance decreased by 12% from 35 mL/min at age 20 to 31 mL/min at 70 years. The decrease after 48 weeks of treatment was 10% from 41 to 37 mL/min between the young</p><p>&nbsp;</p><p>and elderly groups. In addition, pharmacokinetics of lamotrigine was studied in 12 healthy elderly subjects following a 150 mg single dose. The mean clearance in the elderly (0.39 mL/min/kg) lies within the range of the mean clearance values (0.31 to</p><p>0.65 mL/min/kg) obtained in 9 studies with non-elderly adults after single doses of 30 to 450 mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with renal impairment<!--[if supportFields]><span
style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_f38711ee-e6b2-4469-8c47-d42e4ddd448e \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Twelve volunteers with chronic renal failure, and another 6 individuals undergoing haemodialysis were each given a single 100 mg dose of lamotrigine. Mean CL/F were</p><p>0.42 mL/min/kg (chronic renal failure), 0.33 mL/min/kg (between haemodialysis), and</p><p>1.57 mL/min/kg (during haemodialysis) compared to 0.58 mL/min/kg in healthy volunteers. Mean plasma half-lives were 42.9 hours (chronic renal failure), 57.4 hours (between haemodialysis) and 13.0 hours (during haemodialysis), compared to 26.2 hours in healthy volunteers. On average, approximately 20% (range = 5.6 to 35.1) of the amount of lamotrigine present in the body was eliminated during a 4 hours haemodialysis session. For this patient population, initial doses of <em>LAMICTAL </em>should be based on patients&#39; AED regimen; reduced maintenance doses may be effective for patients with significant renal functional impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with hepatic impairment<!--[if supportFields]><span
style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_d649a2c0-f7c2-46ea-b1a5-69132950d42d \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>A single-dose pharmacokinetic study was performed in 24 subjects with various degrees of hepatic impairment and 12 healthy subjects as controls. The median apparent clearance of lamotrigine was 0.31, 0.24 or 0.10 mL/min/kg in patients with Grade A, B, or C</p><p>(Child-Pugh Classification) hepatic impairment, respectively, compared to 0.34 mL/min/kg in the healthy controls. Initial, escalation, and maintenance doses should generally be reduced by approximately 50% in patients with moderate (Child-Pugh Grade</p><p>B) and 75% in patients with severe (Child-Pugh Grade C) hepatic impairment. Escalation and maintenance doses should be adjusted according to clinical response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical efficacy and safety of adjunctive therapy in patients aged 1 to 24 months with partial seizures</strong></p><p>The effectiveness of lamotrigine as adjunctive therapy in patients aged 1 to 24 months with partial seizures was evaluated in a multi-centre, double-blind, placebo-controlled add-on trial (Study LAM20006). Lamotrigine was added to 1 or 2 AEDs during an open-label phase (n=177).</p><p>&nbsp;</p><p>Lamotrigine was given on alternate days or once daily if an initial total dose or</p><p>dose-titration step of less than 2 mg was required. Serum levels were measured at the end of week 2 of titration and the subsequent dose either reduced or not increased if the concentration exceeded 0.41 ug/mL, the expected concentration in adults at this time point. Dose reductions of up to 90% were required in some patients at the end of week 2.</p><p>&nbsp;</p><p>If valproate was used as an AED, lamotrigine was added only after an infant had been on valproate for 6 months without liver function test abnormalities. The safety and efficacy of lamotrigine in patients weighing less than 6.7 kg, and taking valproate or AEDs other than carbamazepine, phenytoin, phenobarbital, or primidone has not been evaluated.</p><p>&nbsp;</p><p>Patients achieving a 40% or greater reduction in partial seizure frequency (n=38) were randomised to either gradual withdrawal to placebo (n=19) or continued lamotrigine (n=19) for up to 8 weeks. The primary efficacy endpoint was based on the difference in the proportion of subjects receiving lamotrigine or placebo who met defined escape criteria. The escape criteria allowed the withdrawal of subjects from the study if their epilepsy conditions showed any signs of clinical deterioration. Statistical significance on the primary endpoint was not achieved; however, fewer patients met escape criteria on lamotrigine (58%) compared with placebo (84%) and took a longer time to meet escape criteria (42 versus 22 days).</p><p>The adverse event profile was similar to that seen in older children.</p><p>&nbsp;</p><p>Clinical efficacy in the prevention of depressive episodes in patients with bipolar disorder:<!--[if supportFields]><span
style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_f8818d36-1219-4839-a00b-5663d6829f07 \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Adults (18 years of age and over)</strong></p><p><strong>&nbsp;</strong></p><p>Two pivotal studies have demonstrated efficacy in the prevention of depressive episodes in patients with bipolar I disorder.</p><p>&nbsp;</p><p>Clinical study SCAB20003 was a multicentre, double-blind, double dummy, placebo and lithium-controlled, randomised fixed dose evaluation of the long-term prevention of relapse and recurrence of depression and/or mania in patients with bipolar I disorder who had recently or were currently experiencing a major depressive episode. Once stabilised using <em>LAMICTAL </em>monotherapy or <em>LAMICTAL </em>plus psychotropic medication, patients were randomly assigned into one of five treatment groups: <em>LAMICTAL </em>(50, 200,</p><p>400 mg/day), lithium (serum levels of 0.8 to 1.1 mMol/L) or placebo for a maximum of 76 weeks (18 months). Treatment regimens were maintained until an emerging mood episode (depressive or manic) deemed it necessary to intervene with additional pharmacotherapy or electroconvulsive therapy (ECT).</p><p>The primary endpoint was &quot;Time to Intervention for a Mood Episode (TIME),&quot; where the interventions were either additional pharmacotherapy or ECT. This endpoint was analysed using three methods of handling data from patients who were withdrawn prior to having an intervention. The p-values for these analyses ranged from 0.003 to 0.029. In supportive analyses of time to first depressive episode and time to first manic/hypomanic or mixed episode, the <em>LAMICTAL </em>patients had longer times to first depressive episode than placebo patients (p=0.047), and the treatment difference with respect to time to manic/hypomanic or mixed episodes was not statistically significant.</p><p>&nbsp;</p><p>&nbsp;</p><p>Clinical study SCAB2006 was a multicentre, double-blind, double dummy, placebo and lithium-controlled, randomised, flexible dose evaluation of <em>LAMICTAL </em>in the long-term prevention of relapse and recurrence of mania and/or depression in patients with bipolar I disorder who had recently or were currently experiencing a manic or hypomanic episode. Once stabilised using <em>LAMICTAL </em>monotherapy or <em>LAMICTAL </em>plus psychotropic medication, patients were randomly assigned into one of three treatment groups: <em>LAMICTAL </em>(100 to 400 mg/day), lithium (serum levels of 0.8 to 1.1 mMol/L) or placebo for a maximum of 76 weeks (18 months). Treatment regimens were maintained until an emerging mood episode (depressive or manic) deemed it necessary to intervene with additional pharmacotherapy or electroconvulsive therapy (ECT).</p><p>The primary endpoint was &quot;Time to Intervention for a Mood Episode (TIME),&quot; where the interventions were either additional pharmacotherapy or ECT. This endpoint was analysed using three methods of handling data from patients who were withdrawn prior to having an intervention. The p-values for these analyses ranged from 0.003 to 0.023. In supportive analyses of time to first depressive episode and time to first manic/hypomanic or mixed episode, the <em>LAMICTAL </em>patients had longer times to first depressive episode than placebo patients (p=0.015), and the treatment difference with respect to time to manic/hypomanic or mixed episodes was not statistically significant.</p><p>In clinical trials, propensity to induce destabilisation, mania or hypomania whilst on</p><p><em>LAMICTAL </em>therapy was not significantly different to placebo.</p><p>&nbsp;</p><p><strong>Pre-clinical Safety Data</strong></p><p>Reproductive toxicology studies with lamotrigine in animals at doses less than the human dose of 400 mg/day [on a body surface area (mg/m<sup>2</sup>) basis] showed developmental toxicity (increased mortality, decreased body weight, increased structural variations, neurobehavioral abnormalities), but<strong><em> </em></strong>no teratogenic effects. However, as lamotrigine is a weak inhibitor of dihydrofolate reductase, there is a theoretical risk of human foetal malformations when the mother is treated with a folate inhibitor during pregnancy.</p><p>&nbsp;</p><p>The results of a wide range of mutagenicity tests indicate that lamotrigine does not present a genetic risk to man.</p><p>&nbsp;</p><p>Lamotrigine was not carcinogenic in long-term studies in the rat and the mouse.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose</p><p>Microcrystalline cellulose Povidone</p><p>Sodium starch glycolate Iron oxide yellow (E172) Magnesium stearate.</p><p>&nbsp;</p><p><em>LAMICTAL </em>tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>N.B. Lactose monohydrate is an excipient of <em>LAMICTAL </em>Tablets only and it is not present in both formulas of Dispersable/Chewable Tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None reported</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Keep dry.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LAMICTAL 25 mg is available in PVC/aluminium foil blister or child resistant PVC/aluminium foil blister. (30 pack size)</p><p>&nbsp;</p><p>LAMICTAL 50 mg and 100 mg are available in PVC/aluminium foil blister or child resistant PVC/aluminium foil/paper blister. (30 pack size)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p><p>&nbsp;</p><p><em>Lamictal is a trademark owned by or licensed to the GSK group of companies.</em></p><p><em>&copy; 2024 GSK group of companies. All rights reserved.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland 

Packed by: 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA 

Marketing Authorisation Holder
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS53/IPI31
Date of issue: 08 July 2024


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>